Clinical Development  
SEG
101, Crizanlizumab 
Oncology Clinical Trial Protocol 
CSEG101A2202 
/ [STUDY_ID_REMOVED]
A phase 2, Multicenter , Open-Label Stud y to Assess PK/PD 
of SEG101 ( crizanlizumab), w ith or without 
Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients 
with Vaso-Occlusive Crisis 
Document  type Amended Protocol Version 
EUDRACT number  Not applicable  
Version number  01 (Amended Protocol Version) Clean 
Development phase  II 
Document status  Final  
Release date [ADDRESS_892759] of abbrev iations  ............................................................................................................ 7 
Glossary  of terms  ................................................................................................................. 9 
Protocol summary .............................................................................................................. 11 
Amendment 01 (04 -Jun-2018)........................................................................................... 14 
1 Background ........................................................................................................................ 18 
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_540708] .............. 18 
1.2 Introduction to investigational treatment(s) and other study treatment(s)  ............. 20 
1.2.1 Overview of  Crizanlizumab (SEG101) ................................................. 20 
2 Rationale  ............................................................................................................................ 24 
2.1 Study rationale and purpose ................................................................................... 24 
2.2 Rationale for the study design  ............................................................................... 24 
2.3 Rationale for dose and regimen  selection  .............................................................. 25 
2.4 Rationale for choice of combination ...................................................................... 25 
2.5 Rationale for choice of comparators drugs ............................................................ 25 
2.6 Risks and benefits .................................................................................................. 25 
3 Objectives  and endpoints ................................................................................................... 26 
4 Study design ...................................................................................................................... 29 
4.1 Description of study design ................................................................................... 29 
4.2 Timi ng of interim analyses and design adaptations  ............................................... 30 
4.3 Definition of end of study ...................................................................................... 31 
4.4 Early  study termination  .......................................................................................... 31 
5 Population .......................................................................................................................... 32 
5.1 Patient  population  .................................................................................................. 32 
5.2 Inclusion criteria  .................................................................................................... 32 
5.3 Exclusion criteria  ................................................................................................... 32 
6 Treatment  ........................................................................................................................... 35 
6.1 Study treatment  ...................................................................................................... 35 
6.1.1 Dosing regimen  ..................................................................................... 35 
6.1.2 Ancillary  treatments  .............................................................................. 35 
6.1.3 Rescue medication  ................................................................................ 36 
6.1.4 Guidelines for continuation of treatment  .............................................. 36 
6.1.5 Treatment  duration ................................................................................ 36 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 30 
Protocol No. CSEG101A2202   
6.2 Dose  escalation guidelines ..................................................................................... 36 
6.3 Dose  modifications  ................................................................................................ 36 
6.3.1 Dose modification and dose delay ........................................................ 36 
6.4 Concomitant medications  ...................................................................................... 47 
6.4.1 Permitted  concomitant therapy .............................................................. 47 
6.4.2 Permitted concomitant therapy requiring caution and/or action  ........... 47 
6.4.3 Prohibited concomitant therapy  ............................................................ 48 
6.4.4 Use of Bisphosphonates (or other concomitant agents) ........................ [ADDRESS_892760]  ......................................................... 75 
8.2 Serious adverse events  ........................................................................................... 76 
8.2.1 Definitions  ............................................................................................. 76 
8.2.2 Reporting ............................................................................................... 76 
8.3 Emergency unblinding of treatment assignment  ................................................... 77 
8.4 Pregnancies  ............................................................................................................ 77 
8.5 Warnings and precautions ...................................................................................... 77 
8.6 Data Monitoring Committee  .................................................................................. 78 
8.7 Steering  Committee  ............................................................................................... 78 
9 Data collection  and management ....................................................................................... 78 
9.1 Data confidentiality  ............................................................................................... 78 
9.2 Site monitoring  ...................................................................................................... 78 
9.3 Data collection  ....................................................................................................... 79 
9.4 Database management and  quality  control ............................................................ 79 
10 Statistical methods and  data analysis  ................................................................................. 80 
10.1 Analysis sets  .......................................................................................................... 80 
10.1.1  Full Analysis Set  ................................................................................... 80 
10.1.2  Safety  set ............................................................................................... 80 
10.1.3  Pharmacokinetic analysis set  ................................................................. 80 
10.1.4  Other  analysis sets  ................................................................................. 81 
10.2 Patient demographics/other b aseline characteristics  .............................................. 81 
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014],  compliance)  ....................... 81 
10.4 Primary  objective ................................................................................................... 82 
10.4.1  Variables  ............................................................................................... 82 
10.4.2  Statistical hypothesis, model, and method of analysis  .......................... 82 
10.4.3  Handling of missing values/censoring/discontinuations ....................... 83 
10.4.4  Supportive and Sensitivity  analyses  ...................................................... 83 
10.5 Secondary  objectives ............................................................................................. 84 
10.5.1  Key secondary  objective(s) ................................................................... 84 
10.5.2  Other secondary  efficacy objectives  ..................................................... 84 
10.5.3  Safety  objectives  ................................................................................... 84 
10.5.4  Pharmacokinetics  .................................................................................. 86 
  86 
10.5.6  Resource utilization  ............................................................................... 86 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 50 
Protocol No. CSEG101A2202   
10.5.7  Patient -reported  outcomes ..................................................................... 86 
10.5.8  Immunogenicity .................................................................................... 86 
  86 
 
 86 
  86 
  87 
  88 
  89 
10.7 Interim analysis  ...................................................................................................... 89 
10.8 Sample  size calculation  .......................................................................................... 89 
10.9 Power for analysis of key secondary  variables  ...................................................... 90 
11 Ethical considerations and  administrative  procedures  ....................................................... 91 
11.1 Regulatory and ethical compliance  ........................................................................ 91 
11.2 Responsibilities of the investigator  and IRB/IEC/REB  ......................................... [ADDRESS_892761] keepi[INVESTIGATOR_5304] ....................... 92 
11.7 Confidentiality of study documents and patient records ....................................... 93 
11.8 Audits and inspections ........................................................................................... 93 
11.9 Financial  disclosures  .............................................................................................. 93 
12 Protocol adherence  ............................................................................................................ 93 
12.1 A
mendments to  the protocol .................................................................................. 94 
13 References (available upon request)  .................................................................................. 95 
14 Appendices ........................................................................................................................ 98 
14.1 Appendix 1 – List of prohibited CYP3A inhibitors and inducers .......................... 98 
14.2 Appendix 2 – List of prohibited  QT-prolonging drugs .......................................... [ADDRESS_892762] of tables 
Table 3-1 Objectives and  related  endpoints ........................................................... 27 
Table 6-1 Dose and  treatment schedule ................................................................. 35 
Table 6-2 Criteria for dose reduction / interruption and re- initiation of 
crizanlizumab treatment for adverse drug reactions.  ............................ [ADDRESS_892763] of VOC Events Not Requiring AE/SAE  Reporting ....................... [ADDRESS_892764]  
ALT Alanine aminotransferase / glutamic pyruvic transaminase /GPT  
AST Aspartate aminotransferase / glutamic oxaloacetic transaminase/GOT 
AUC  Area Under the Curve  
BSA Body Surface Area  
CDP  Clinical Development  Plan 
CRD  Chronic Renal  Disease  
CRF Case Report/Record Form; the term CRF can be applied to either EDC or  Paper 
CRO  Contract Research Organization  
CSR  Clinical study  report  
CSR  
addendum  An addendum to Clinical Study Report (CSR) that captures all the additional 
information that is not included in the CSR  
CTCAE  Common Terminology Criteria for Adverse Events 
DLT Dose Limiting Toxicity  
DMC  Data Monitoring Committee  
CMO&PS  Chief Medical Office and Patient Safety 
ECG  Electrocardiogram  
ER Emergency  Room  
FAS Full Analysis  Set 
FMI Final Market  Image  
Hb Hemoglobin  
HbA Hemoglobin A 
HbS Human hemoglobin S (sickle cell  hemoglobin)  
HbSC  Heterozygous sickle Hemoglobin C disease (hemoglobin SC disease)  
HbS β Heterozygotes  with one copy  of the HbS gene  and a β-thalassemia variant  (β0 or 
β+) 
HbSS  homozygous  sickle  cell disease (hemoglobin SS disease) 
HU/HC  Hydroxyurea/Hydroxycarbamide  
GFR  Glomerular Filtration Rate  
i.v. intravenous(ly)  
ICH International Conference on Harmonization  
IEC Independent Ethics  Committee  
IRB Institutional Review  Board  
ITT Intent -to-treat 
LDH Lactate dehydrogenase  
MAP  Master Analysis Plan documents project standards in the statistical methods which will be used within the individual clinical trial RAP documentation  
MDRD- GFR  Modification of Diet in Renal Disease- Glomerular Filtration  Rate  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 80 
Protocol No. CSEG101A2202   
 
NSAID(s) 
PAS Non- Steroidal Anti -Inflammatory Drug(s) 
Pharmacokinetic Analysis Set  
PD Pharmacodynamics  
PDS Pharmacodynamics Analysis  Set 
PHI Protected Health Information 
PK Pharmacokinetics  
PKPDS  Pharmacokinetic -Pharmacodynamics Analysis  Set 
popPK  Population PK 
PSGL -1 P- selectin glycoprotein ligand-1 
RAP The Report and Analysis Plan (RAP) is a regulatory document which  provides 
evidence of preplanned analyses  
REB Research Ethics  Board  
RR Risk Ratio  
SAE Serious Adverse Event  
SCD  Sickle Cell Disease  
SCPC  Sickle Cell- related Pain Crises  
SOP  Standard Operating  Procedure 
VOC  Vaso -Occlusive  Crisis  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 90 
Protocol No. CSEG101A2202   
 
Glossary of terms 
 
 
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject or study 
patient  
Cohort  A group of newly enrolled patients treated at a specific dose and 
regimen (i.e. treatment group) at the same time  
Dose level  The dose of drug given to the patient (total daily or weekly etc.)  
Enrollment  Point/time of patient entry into the study; the point at which informed 
consent must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)  
Investigational drug  The study treatment whose properties are being tested in the study; 
this definition is consistent with US CFR 21 Section 312.3 and is 
synonymous with “investigational new drug.”  
Medication number  A unique identifier on the label of each study treatment pa ckage 
which is linked to one of the treatment groups of a study  
Other study treatment  Any drug administered to the patient as part of the required study 
procedures that was not included in the investigational treatment  
Period  A subdivision of the study timeline; divides stages into smaller 
functional segments such as screening, baseline, titration, washout, 
etc. 
Perpetrator drug  Drug which affects the pharmacokinetics of the other drug  
Personal Data  Subject information collected by [CONTACT_5336]. This data includes 
subject identifier information, study information and biological 
samples.  
SEG101  [COMPANY_001] supply of crizanlizumab  
SelG1  Reprixys supply of crizanlizumab  
Stage related to study 
timeline  A major subdivision of the study timeline; begins and ends with 
major study milestones such as enrollment, randomization, 
completion of treatment, etc.  
Stop study participation  Point/time at which the patient came in for a final evaluation visit or 
when s tudy treatment was discontinued whichever is later  
Study treatment  Includes any drug or combination of drugs in any study arm administered to the patient (subject) as part of the required study procedures, including placebo and active drug run- ins. 
In specific examples, it is important to judge investigational treatment component relationship relative to a study treatment combination; study treatment in this case refers to the investigational 
and non -investigational treatments in  combination.  
Study treatment 
discontinuation  Point/time when patient permanently stops taking study treatment for 
any reason  
Subject Number  A unique identifying number assigned to each 
patient/subject/healthy volunteer who enrolls in the study  
Variable  Identifier used in the data analysis; derived directly or indirectly from 
data collected using specified assessments at specified timepoints  

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892765]  
Withdrawal of study consent  Withdrawal of study  consent: Withdrawal of consent from the study 
occurs only when a subject does not want to participate in the study any longer, and does not allow any further collection of personal 
data 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 11
0 Protocol No. 
  
 
Protocol summary:  
Title A phase 2, Multicenter, Open -Label Study to Assess PK/PD of SEG101 
(crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in 
Sickle Cell Patients with Vaso -Occlusive Crisis  
Brief title  Pharmacokinetics and pharmacodynamics study of SEG101  
(crizanl izumab) in Sickle Cell Disease (SCD) patients with Vaso- 
Occlusive Crisis (VOC)  
Sponsor and Clinical 
Phase  [COMPANY_001] 
Phase II  
Investigation type  Drug  
Study type  Interventional  
Purpose and rationale  Crizanlizumab is a humanized monoclonal antibody that binds P -selectin 
and was previously found to reduce the median annualized rate of VOC 
at 5 mg/kg by 45.3% compared to placebo. Clinical and toxicological studies performed to date for crizanlizumab were conducted using 
Reprixys material (SelG1 mAb). To ensure supply of future clinical studies as well as commercial demand, [COMPANY_001] has optimized the production of crizanlizumab. The [COMPANY_001] material (SEG101 mAb) drug 
substance (DS) and drug product (DP) will be manufactured at [COMPANY_001] 
sites. The change in manufacturing cell line is not expected to impact the bioavailability or activity of the compound.  
The purpose of the CSEG101A2202 study is to characterize the PK and 
PD of SEG101 and to evaluate the saf ety and efficacy of SEG101.  
Primary Objective(s) and Key Secondary Objective  To characterize PK of crizanlizumab at 5.0 mg/kg in SCD patients.  
To characterize PD (P -selectin inhibition) of crizanlizumab at 5.0 mg/kg 
in SCD patients  
Secondary Objectives  To assess the efficacy of crizanlizumab in SCD patients in terms of annualized rate of VOC events leading to healthcare visit in clinic/ER/hospi[INVESTIGATOR_307], annualized rate of VOC events treated at home, 
annualized rate of hospi[INVESTIGATOR_510727], annualized rate of 
ER/hospi[INVESTIGATOR_059], annualized rate of each subcategory of VOC event (uncomplicated pain crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapi[INVESTIGATOR_8801]), annualized rate of VOC events.  
To assess the safety and tolerability of crizanlizumab in terms of the number, seriousness, severity, and causality assessments of treatment 
emergent adverse events and other safety data as considered 
appropriate and absolute change from baseline in hemoglobin  
Study design  Open -label, single a rm study of crizanlizumab therapy in SCD patients.  
Population  [ADDRESS_892766] 1 VOC over the preceding 12 months, and who are not planning to 
take HU/HC during the trial or are receiving stable treatment with 
HU/HC.  
Inclusion criteria  • Male  and non-pregnant  female  patients  16-70 years  of age (inclusive)  
• Confirmed diagnosis of sickle cell disease by [CONTACT_661872]- performance liquid chromatography (HPLC) 
[performed locally]. All sickle cell disease genotypes are eligible.  
• Exper ienced at least 1 VOC within the preceding 12 months prior to 
Screening, as determined by [CONTACT_9870].  
• If receiving HU/HC or erythropoietin stimulating agent, must have 
been receiving the drug for at least 6 months prior to  Screening  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 12
0 Protocol No. 
  
 
 • Hemoglobin ≥4.0 g/dL. Absolute neutrophil count ≥1.0 x 109/L and 
platelet count ≥75 x 109/L 
• Adequate renal and hepatic function as  defined:  
• GFR ≥45 mL/min/1.73 m2 calculated by  [CONTACT_9289] -EPI 
• ALT ≤[ADDRESS_892767] 
• Direct (conjugated) bilirubin ≤[ADDRESS_892768] 
• ECOG performance st atus ≤2 
• Written informed consent prior to any screening  procedures  
Exclusion criteria  • History of stem cell  transplant.  
• Acute VOC ending within 7 days of W1D1 dosing 
• Received blood products within 30 days prior to W1D1 dosing.  
• Participating in a chronic transfusion program (pre- planned series of 
transfusions for prophylactic  purposes)  
• History of severe hypersensitivity reactions to other monoclonal 
antibodies  
• Received a monoclonal antibody or immunoglobulin -based agent 
within 1 year of Screening, or has documented immunogenicity to a 
prior biologic.  
• Received active treatment on another investigational trial within 30 
days (or 5 half -lives of that agent, whichever is greater) prior to 
Screening  
• Significant active infection or immune deficiency (including chronic 
use of immunosuppressive drugs) in the opi[INVESTIGATOR_871]  
• Resting QTcF ≥470 msec at pretreatment (baseline) or other cardiac 
or cardiac repolarization  abnormality  
Investigational and 
reference therapy  SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for 
exploratory  group)  by [CONTACT_12781]  30 min on week  1 day 1, week 
3 day 1, and then day 1 of every 4 -week  cycle.  
Efficacy assessments  -VOCs leading to healthcare visit in clinic/ER/hos pi[INVESTIGATOR_307] 
-VOCs treated at home, based on documentation by [CONTACT_661873]  
-Each subcategory of VOC event (uncomplicated pain crisis, acute chest 
syndrome, hepatic sequestration, splenic sequestration, priapi[INVESTIGATOR_8801])  
-Hospi[INVESTIGATOR_510727] (both overall and VOC -related)  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 13
0 Protocol No. 
  
 
Safety assessments  Safety will be monitored by [CONTACT_339555]:  
-Vital signs  
-Physical exam  
-ECG in triplicates at all PK assessment timepoints [central review]  
-Hematology, blood chemistry, coagulation and urinalysis (additional 
laboratory tests will be performed at the investigator’s discretion for 
safety measures in the event of an adverse event)  
-Pregnancy  
 
 
 
-Monitoring of AEs/SAEs  
Data analysis  PK parameters including AUC and Cmax will be derived from individual 
concentration- time profiles after the first dose and the 5th dose. The 
inter-subject variations and CV% will be presented for the primary PK 
parameters. The point estimate and the corresponding two- sided 90% 
confidence interval (CI) for the mean of the log- transformed primary PK 
parameters after single dose and multiple doses will be derived 
respectively. The point estimate and CI will be anti -log transformed to 
obtain the point estimate and the 90% confidence interval for the  
geometric mean on the original scale. The descriptive statistics (n, mean, 
CV%, standard deviation (SD), median, geometric mean, geometric CV%, minimum and maximum) will be presented for all PK parameters except Tmax,  where only n, median, minimum and maximum will be 
presented. Descriptive statistics for crizanlizumab concentration will be presented at each scheduled timepoint.  
PD-AUCd15 and PD -AUCd29 will be derived from the %P- selectin 
inhibition time profiles of week 1 and week 15, respectively. The point estimate and the corresponding two- sided 90% CI for the mean of the 
log-transformed PD -AUC after single dose and multiple doses will also 
be provided. The point estimate and CI will be anti -log transformed to 
obtain the point estimate and the 90% confidence interval for the geometric mean on the original scale. Descriptive statistics for PD 
inhibition will be presented at each scheduled timepoint.  
Key words  Sickle cell disease, sickle cell anemia, vaso -occlusive cri sis, P -selectin  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 14
0 Protocol No. 
  
 
Amendment 01 (04- Jun-2018)  
Amendment rationale  
The study is currently open for enrollment with 21 subjects enrolled to date. 
Due to the ongoing high unmet medical need for prevention of VOC in SCD, particularly for 
patients age <18 years old, and the unexpected delay in start of the SEG101 phase 2 (CSEG101B2201) trial for ages 6 months to 18 years, the decision was made to expand the inclusion age in CSEG101A2202 to include 16 and 17 year old subjects. This is based on the well-established and widely- accepted view that there is no meaningful difference in PK 
between adolescents (here ages 16 -<18 years) and adults 18 years and older. Monoclonal 
antibodies are distributed within the vascular and extracellular spaces by [CONTACT_661874], and predominately catabolized by [CONTACT_661875]. It is unlikely that these (the vascular and extracellular fraction in the 
body and enzyme activity)  differ  in age [ADDRESS_892769] provided feedback after enrolling their initial patients to the 
study. They suggested the protocol inclusion and exclusion criteria be examined and modified regarding the timing of prior VOCs and historical testing informat ion as well as current 
treatment be clarified.  
This amendment also clarifies that the VOC events should not be reported as adverse events. 
Further review of the secondary endpoints led to the changes from the number of efficacy 
related endpoints to the annualized (rates) – this accounts for any early subject withdrawal by 
[CONTACT_661876] a standard time period.  
Additional PK samples have been added to align with the IG sample collection timelines. Additional safety information has led to the adjustment of the dose modification guidance for this compound, including the removal  of the dosing modification  requirements for hypertension, 
the addition of dosing modification guidelines for QTc prolongation, as well the correction of editorial and typographical errors.  
 
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underline for insertions. 
• Throughout: Typographical and grammatical errors addressed.  
• Throughout: Removed references to “adult” in protocol title, objectives, study design, endpoints. 
• Abbreviations: Added NSAID  
• Glossary: Added definitions for personal data and withdrawal of study consent. Removed supportive treatment from glossary. 
• Section 2.3: Clarified the two doses and the future Phase III trial design. 
• Section 2.6: Removed pre- clinical  information.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 15
0 Protocol No. 
  
 
• Table 3.1: Revised primary  objective from trough to pre-dose 
concentrations. Revised the secondary  endpoints from number, to 
annualized (rates).  
 
• Section 4.1: Clarified HU/HC dosing requirements. Removed requirement to be off 
HU/HC for 6 months if taking HU/HC at time of enrollment. Changed scr eening  window 
from [ADDRESS_892770] amendment changes.  
• Section 4.2: Added provision for additional ad hoc analyses. Revised interim analysis from will be, to may be performed. Revised the potential impact of the interim analysis.  
• Section 4.3: Clarified end of study participation criteria  
• Section 5.1: Revised patient population to include 16-17 year olds in the population 
• Section 5.2: Changed inclusion age to 16 from 18 years in inclusion criteria #1 
• Section 5.2: Clarified definitions for VOC treatments in inclusion criteria  #3 
• Section 5.2: Removed inclusion cri teria #5 – chest  X-ray 
• Section 5.3: Revised exclusion #[ADDRESS_892771] dose, instead of 15 days prior to screening. Removed Exclusion criteria #13 requiring male contraception due to monoclonal antibody pregnancy guidance. Revised exclusion criteria #[ADDRESS_892772] only present on imaging. Revised exclusion criteria #19 to allow for well controlled HIV positive subjects to be included. 
• Section 6.3.1: Revised the missed doses requirement for discontinuation to reflect 2 consecutive missed for any reason within a 10 week period. 
• Table 6.2: Clarified total bilirubin to be total bilirubin (direct [conjugated] and/or total). Deleted hypertension dose modification requirements as per the change in program standard  language.  
• Section [IP_ADDRESS]: Added section of dose adjustments for QTcF prolongation. 
• Section 7.1: Changed screening window from 28 to 35 days. 
• Table 7 -1: Changed screening window to [ADDRESS_892773] 
dose.  
• Section 7.1.2: Revised re-screening numbering per the new database standards. Changed screening window to 35 days. Removed sentence regarding ICF timing for re-screening. 
• Section 7.1.4: Revised to clarify the timing of the full PK/PD profiles if a dose is interrupted. 
• Section [IP_ADDRESS]: Deleted replacement policy section as Not Applicable.  
• Section 7.1.6: Update withdrawal of consent section to reflect current [COMPANY_001] legal language 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 16
0 Protocol No. 
  
 
• Section 7.2.1: Clarified language regarding end date for VOC based on pain medication 
management.  Updated  definition  of ACS  based  on symptoms and end of priapi[INVESTIGATOR_661832] 2 hours 
from 1 hour. Removed requirement to hold dosing until VOC resolves. Added sentence “VOC  is not a known contra-indication, but dosing during a crisis  should be at investigator’s 
discretion”. Clarified medications for VOC  definitio n. 
• Table 7 -2: Updated table to add optional PK/PD samples around transfusion. Added 
optional PK, soluble P-selectin and PD samples at onset and resolution of VOC events.  
• Section [IP_ADDRESS]: Clarified laboratory testing should be done centrally unless otherwis e 
noted. 
• Table 7 -3: Updated to reflect which are local and which are central laboratory  tests.  
• Section [IP_ADDRESS].5 Added “if central laboratory results are unevaluable or inconclusive” as a criteria to draw local  labs 
• Section [IP_ADDRESS].2: Revised to note that blood alcohol test will be performed locally  
• Section [IP_ADDRESS].3: Revised to note that the macroscopic urinalysis will be done locally and the microscopic will be done centrally.  
• Section [IP_ADDRESS].5.: Revised to reflect the serum pregnancy testing will be performed 
centrally and the urine pregnancy testing will be performed locally.  
• Section [IP_ADDRESS].6: Added section regarding the Hepatitis markers testing.  
•  
 
  
 
•  
 
  based on tubes to be used. 
• Table 7.5: Added PK samples 33-38 (Weeks 75, 99, 123,147, 171). Added Follow up Phase time point and samples for PK and IG. Updated number of doses needed to reach 
steady state if dose(s)  missed.  
• Section 8.1.1.: Removed sentence about VOC not being reported as AEs.  
• Section [IP_ADDRESS] and Table 8-1: Added section on Protocol Exempt AEs and SAEs.  
• Section 8.2.1: clarified VOCs not SAEs  
• Section 9.3: Added missing part of sentence for reconciliation of information. 
• Section 10: Added clarification that 5.0 mg/kg enrollment will end at [ADDRESS_892774]. 
• Section 10.1.3: Added clarification regarding the timing of the full PK/PD profiles if a 
dose is interrupted. 
• Section  [IP_ADDRESS]: Added clarification  regarding the timing  of the full PK/PD  profiles  if a 
dose is interrupted. 
• Section 10.5.2: Changed secondary efficacy objectives from number of to annualized rate 
of VOC events and hospi[INVESTIGATOR_602]. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 17
0 Protocol No. 
  
 
  
 
  
 
•
 Section 10.7: Added provision for additional ad hoc analyses.  
• Section 13: Updated the references  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional  Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 18
0 Protocol No. 
  
 
1 Background 
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_661833] (SCD) is a rare autosomal recessive blood disorder caused by a single 
missense mutation (Glu6Val) in the β -globin gene that renders the mutant hemoglobin less 
soluble and prone to polymerization upon deoxygenation. The polymerization of hemoglobin causes deformation of the erythrocyte to give the cell a “sickle” shape ( Bookchin 1996), and 
leads to chronic hemolysis, anemia, and vaso- occlusion ( NHLBI, The Management of Sickle  
Cell Disease. NIH Publication No.022117; Wethers 2000 ). SCD is the most common single 
gene disorder in African Americans, affecting approximately 1 in 375 -600 persons of African 
ancestry ( Clinical Practice Guideline No. 6. April 1993; Nietert 2002). Sickle cell conditions 
are also  common among people of Mediterranean  countries, Africa,  the Caribbean  and parts  of 
South and Central America ( Clinical Practice Guideline No. 6. April 1993; Nietert  2002).  
In SCD,  lysis of sickle  red cells,  cell membrane damage and  oxidative stress,  repeated  ischemic 
damage, and microvasculature injury are due to the adhesive interactions between sickle red cells and the endothelium, which  culminate  in a pro-inflammatory  environment ( Embury 2004; 
Chiang 2005). In this environment of chronic vascular inflammation, the adherence of 
leukocytes, platelets  and sickle  red cells to activated  blood vessel  endothelium and to each other 
is believed to be the primary cause of microvasculature blockage and vaso -occlusive crisis 
(VOC), the clinical hallmark of SCD, typi[INVESTIGATOR_661834]. Additional factors such as the rigidity  of sickle  red cells,  increased  blood viscosity, and local  vasoconstriction have 
also been identified as potentially contributing to the vaso- occlusion process. VOC includes 
pain crises (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso- occlusion and which requires therapy with oral or parenteral 
opi[INVESTIGATOR_661835])  as well as other complicated  crises,  such as acute  chest  syndrome 
(ACS),  priapi[INVESTIGATOR_8801],  and hepatic or splenic sequestration  (Maitre  et al. 2000; Vichinsky et al. 2000). 
VOC accounts for over 90% of hospi[INVESTIGATOR_661836] ( Matsui et al. 2001; 
Chiang 2005; Okpala 2006).  
SCD patients also suffer from cerebrovascular complications, ranging from clinically evident acute stroke to transient silent ischemic infarct ( Platt 2006). Other chronic complications 
include functional asplenia, leaving pat ients more susceptible to infection, ( Clinical Practice  
Guideline No. 6. April  1993),  bone growth  retardation  and avascular  necrosis  renal  dysfunction 
(Saborio 1999), and issues of the biliary tree (gallstones, congestion), eyes (retinopathy) 
(Ch
arache 1996),  and soft tissue  (leg ulcers)  (Ashley -Koch  2000; Gladwin  et al., 2004; Gladwin  
2005). Chronic pain and opi[INVESTIGATOR_661837] ( Smith 1996). As a result, there is an 
approximately 20 to 30 year reduction in life expectancy in SCD patients ( Platt et al.  1994).  
Hemoglobin values for SCD patients vary, but typi[INVESTIGATOR_381599] 6 to 10 g/dL, but some patients can live with a baseline hemoglobin of 4 g/dL  or lower. Chronic hemolysis results in 
other abnormal labs, including reticulocytosis,  low haptoglobin, and increased  free hemoglobin, 
LDH, indirect bilirubin (and, by [CONTACT_66250], total bilirubin). In young SCD patients, glomerular 
filtration  rate (GFR)  is substantially  increased  (hyperfiltration: MDRD- GFR  >130 in women, 
>140 ml/min per 1.73 m2 in men) but tends to decrease progressively with time, and 4- 5% of 
these patients in the US develop stage 5 chronic renal disease (CRD) (Hirschberg 2010). SCD  

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892775] erythropoiesis 
and lead to aplastic crisis ( Heegaard 2002 ). 
SCD has three common variants: homozygous SCD (hemoglobin SS disease), doubly 
heterozygous sickle hemoglobin C disease (hemoglobin SC disease) and the sickle β - 
thalassemia.  The most common  and severe form  of the disease occurs  in individuals who inherit 
two copi[INVESTIGATOR_661838] (HbSS) and the primary hemoglobin in their red blood cells is sickle  hemoglobin. Other  individuals can be affected  as compound heterozygotes  with one copy 
of the HbS gene and one or more additional mutations, resulting in varying severities of the disease. HbSC results in a mild -to-moderate form of the disease. HbS β -thalassemia variants 
(β
0 or β+) result in a range of clinical severities: HbSβ0 is a se vere form, whereas HbSβ+ can be 
moderate or mild based  on the contribution of each variant  to the total hemoglobin of the patient. 
Other  more  rare variants  can result  if in addition to the HbS gene,  another abnormal  hemoglobin 
is inherited from the other p arent, such as D, G or O -Arab. The sickle red cells gene is most 
commonly present in individuals heterozygous for HbS and HbA. These individuals carry the sickle cell trait and are asymptomatic (Clinical Practice Guideline No. 6. April 1993; Nietert e t 
al. 2002).  
All individuals that are homozygous or compound heterozygous for HbS show some clinical 
manifestations of SCD. Clinical signs appear within the first 6 months of life but there is considerable variability in severity ( Gill et al. 1995). Disease severity is thought to depend on 
a complex interaction of genetic, rheologic and hematologic factors, as well as microvascular and endothelial factors. Therefore, despi[INVESTIGATOR_661839], the ability to predict diseas e course from birth is limited ( Thomas 1997). The frequency of VOC and pain 
severity varies considerably among patients and in the same patient over time. Moreover, a recent study (Pi[INVESTIGATOR_352757]) evaluating health related quality of life issues in SCD patients  indicated 
that VOC might be significantly underreported among SCD patients ( McClish et al.  2005).  
Treatment for SCD includes supportive care for VOC. The two most common symptomatic treatments  are blood transfusions and analgesics.  Blood transfusions both increase hemoglobin 
level and lower the proportion of sickled cells, thereby [CONTACT_661877]. Severe pain is often treated with narcotics but their use is controversial due to concerns of narcotic addiction and tolerance. Other complications of narcotic use are drug -seeking behavior, sedation and respi[INVESTIGATOR_2341]. Oxygen 
management has been utilized to treat VOC, despi[INVESTIGATOR_661840]. Rehydration is also used during VOC with some apparent benefit ( NHLBI , The 
Management of Sickle Cell Disease. NIH Publication No.022117; Yale 2000).  
Preventative therapi[INVESTIGATOR_661841]- risk patients, Hydroxyurea/Hydroxycarbamide (HU/HC, 
Droxia/Siklos) is approved for VOC.  The mechanisms  by [CONTACT_661878]/HC  produces its beneficial 
effects are uncertain but likely involve increasing hemoglobin F levels in RBCs, thereby [CONTACT_661879] S polymerization. Hydroxyurea is cytotoxic, myelosuppressive and teratogenic ( Charache et al. 1995 ), and the long- term effects of 
hematologic toxicities, organ damage and carcinogenicity are currently unknown ( NIH 
Consensus and State -of -the Science Statements 2008 ). L-glutamine was recently approved by 
[CONTACT_661880]  5 years 
and older. Bone marrow  transplantation  may be considered and can be curative,  but a limited  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 20
0 Protocol No. 
  
 
number of patients are eligible, and this carries a high risk of morbidity and mortality ( NHLBI  
The Management  of Sickle Cell Disease. NIH Publication No.022117). Thus, SCD is a life - 
threatening disease with severe morbidities and represents a major unmet medical need.  
The recognition that adherence of leukocytes, platelets and sickle red cells to blood vessel 
endothelium and to each other to have a primary role in VOC led to further research into the 
selectins,  which  mediate the first steps  in the recruitment of leukocytes  to specific  tissues.  Under 
shear flow in the blood, leukocytes first tether and begin rolling on vascular endothelium, eventually  adhering  firmly  and infiltrating  into the underlying tissue  (Springer 1995).  Selectins 
interact with glycoconjugated ligands on leukocytes to initiate this process ( McEver 1995; 
Vestweber 1999). Transient adhesion mediated by [CONTACT_661881] a prerequisite for firm adhesion  
mediated by [CONTACT_661882]. Three selectins have been identified: P -, E- and L -selectin. P -selectin is the best characterized of the 
selectins and binding specificity and affinity to its physiological ligand P-selectin glycoprotein ligand- 1 (PSGL -1) is well- documented ( McEver 2004; Mehta 1998). P -selectin is stored in 
Weibel -Palade bodies in endothelial cells that line blood vessels and in α -granules in  platelets.  
Extensive data have been published over the last decade that suggests a pi[INVESTIGATOR_49297] P - 
selectin in the pathophysiology of SCD ( Matsui 2001). Much of this work has been conducted 
in mice engin eered or altered to express human hemoglobin S (sickle cell hemoglobin) but not 
mouse β hemoglobin. These mice have a remarkably similar disease pathology and inflammatory profile to that observed in human SCD, including vaso- occlusion. Using these 
mice, i nvestigators have demonstrated P -selectin interactions between the endothelium and 
sickled red blood cells, leukocytes, and platelets. Additional studies have demonstrated direct P-selectin -mediated  binding of leukocytes with sickled  red cells and platelet s. All of these cell- 
cell interactions have been implicated in SCD vaso -occlusion. Further, blockade or genetic 
absence of P -selectin decreases or eliminates these cell -cell interactions and vaso-occlusion. 
Taken  together, these studies establish  P-selectin  as a key mediator  of vaso-occlusion in SCD.  
 
1.2 Introduction to investigational treatment(s) and other study 
treatment(s) 
1.2.1  Overview of Crizanlizumab  (SEG101)  
Crizanlizumab  (SEG101) is  a humanized  monoclonal antibody that  binds P- selectin  in humans 
and primates and blocks the interaction of P -selectin with its ligands. The compound was 
previously developed by [CONTACT_661883],  SelG1,  and subsequently 
became a legal entity of [COMPANY_001] Pharmaceuticals on  18-Nov-2016. 
 
[IP_ADDRESS]  Non-clinical  experience  
Crizanlizumab is administered intravenously (i.v.) with instantaneous absorption and assumed 
100% bioavailability. As a humanized, monoclonal antibody, distribution is expected to be 
typi[INVESTIGATOR_661842], f luid-phase endocytosis, receptor -mediated  endocytosis 
and their interaction with FcRn receptors ( Heegaard 2002). Crizanlizumab contains only 
naturally occurring amino acids and has no known active metabolites. Human antibodies are 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 21
0 Protocol No. 
  
 
predominately catabolized  by [CONTACT_661884].  The extent 
of catabolism  is inversely  proportional to FcRn  receptor affinity  (Dall’Acqua et  al. 2002).  
No specific studies have been conducted to evaluate specific pathways of crizanlizumab 
excretion. Due to its predicted molecular size of approximately 148 kDa, it is expected that crizanlizumab, like other immunoglobulins, is not eliminated by [CONTACT_661885]. 
In addition to studies in rodents containing human sickled hemoglobin, other studies 
demonstrated that human sickled red cells adhere to human endothelial cells more frequently than normal red cells, and an anti -human P-selectin antibody inhibits this adherence ( Matsui  et 
al. 2001).  
In experiments performed with the parental anti -human P -selectin antibody G1, the following 
data were  generated:  1) G1 blocks  the binding of human P- selectin  to its ligand PSGL -1 (Geng  
et al. 1990) 2) G1 blocks leukocyte rolling and firm adhesion to human vascular endothelium under shear  stress ( Geng  et al. 1990; Jones et al. 1993);  3) G1 effectively  inhibits  the interaction 
of neutrophils with stimulated  platelets  (Hamburger 1990);  4) G1 completely  blocks the binding 
of human sickled red cells to human endothelium under flow ( Wagner 2006 ); and 5) in mice 
expressing human but not  mouse P- selectin,  G1 blocks the rolling  and adherence  of leukocytes 
on mouse venules and can reverse  pre-established  leukocyte adhesion  (Liu et al. 2010).  
In experiments performed to confirm that the humanized form of G1 (SelG1) shares identical specificity and function with parental G1, SelG1 was shown to 1) bind P -selectin with an near 
identical affinity to that of G1; 2) maintain the same species restriction pattern as G1; 3) have the same epi[INVESTIGATOR_661843] G1; 4) effectively block the binding of P -selectin to its 
receptor on human cells and; 5) retain the receptor/ligand dissociative property of G1. 
Due to the species restriction of SelG1 binding, much of the data available to date have been 
obtained from rodent modeling using mice expressing human hemoglobin S (sickle cell hemoglobin) with surrogate antibodies that block mouse P -selectin or animals genetically 
deficient in P -selectin. Where possible, the SelG1 parental antibody G1 has been used in 
experimentation in which human P -selectin is present. In addition, confirmatory data with 
SelG1 were estab lished. 
In mice expressing human sickled hemoglobin (human β
S mice) the following data were 
generated: 1) an anti -mouse P -selectin antibody blocks leukocyte rolling ( Kaul 2000); 2) vaso- 
occlusion is blocked in animals  deficient  in P-selectin  (Frenette  2004);  3) platelet  and leukocyte 
adhesion to vascular  endothelium is absent  in P-selectin  deficient  animals  (Wood 2004);  an d 4) 
sickled red cell microvascular f low is increased and vaso- occlusion decreased with an anti - 
mouse P-selectin antibody ( Embury et al. 2004).  
Finally, SelG1 has been administered to nonhuman primates in a single -dose and two separate 
GLP multi- dose studies. Administration of SelG1 by [CONTACT_661886] 4 weeks to 
cynomolgus monkeys for a total of seven doses was well tolerated at doses ≤ 25 mg/kg/dose; the no observed adverse effect level (NOAEL) is therefore 25 mg/kg/dose. 
As SelG1  is specific to human and nonhuman primate  P-selectin  and in accordance  with the ICH 
S6 Guidance,  no genotoxicity or reproductive toxicology studies have been  performed  to date.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 22
0 Protocol No. 
  
 
[IP_ADDRESS]  Clinical experience  
 
Phase I Clinical Study (CSEG101A2101)  
The objectives of this study (Reprixys study code: Se1G1- [ZIP_CODE]; [COMPANY_001] study code: 
CSEG101A2101) were to evaluate the safety, PK, PD, and immunogenicity of intravenously 
administered  SelG1  versus  placebo  in 27 healthy subjects  at ascending  dose levels  (0.2, 0.5, 1.0, 
5.0 mg/kg and 8.0 mg/kg). 
Crizanlizumab concentrations slowly declined, with mean half -life ranging from 75.6 (at dose 
of 0.2 mg/kg) to 500 (at 5.0 mg/kg) hours. Therefore, clearance decreased with the increase in 
dose level: 88.6 mL/hr. (at 0.2 mg/kg) to 9.91 (at 5.0 mg/kg). Following two intravenous infusions of SelG1 at 8.0 mg/kg, the mean half -life was 363 hours, and the clearance was 3.86 
mL/hr.  For subjects receiving  a single dose of crizanlizumab  at 5.0 mg/kg, P- selectin  inhibition 
was complete for at least 28 days with a mean crizanlizumab concentration on Day 28 of 19.9±3.8 μg/mL.  
There were no infection -related AEs, changes in coagulation parameters, increased bleeding 
tendencies, or notable  treatment- related changes in peripheral blood immunophenotypi[INVESTIGATOR_007]. The 
immunogenicity  data generated  during the Phase I clinical  trial indicate  that no specific antibody 
response to SelG1 occurred in any subjects receiving up to 2 doses of drug. 
Based  on AEs,  clinical  laboratory evaluations, vital signs measurements,  physical examinations, 
and ECG evaluations, administration of SelG1 was safe and well -tolerated in this group of 
healthy male and female subjects.  
 
Phase II Clinical Study (SUSTAIN – CSEG101A2 201) 
The purpose of SUSTAIN (Reprixys study code: Se1G1- [ZIP_CODE]; [COMPANY_001] study code: 
CSEG101A2201) study was to investigate the safety and tolerability of the humanized anti -P- 
selectin monoclonal antibody, crizanlizumab (SelG1), during chronic administration to SCD 
patients and to investigate the efficacy of crizanlizumab to affect the rate of sickle cell -related 
pain crises (SCPC) (also known as VOC leading to a healthcare visit) as well as a variety of other clinical endpoints, anemia - and hemolysis -related laboratory parameters, 
pharmacokinetics/pharmacodynamics (PK/PD), and patient reported outcomes. 
This trial was a multicenter,  randomized, placebo -controlled, double-blind, parallel -group study 
to assess the safety and efficacy of crizanlizumab versus p lacebo in patients with SCD, both 
receiving  and not receiving  HU/HC.  Crizanlizumab  was administered  at 2 different  dose levels 
(2.5 mg/kg and 5.0 mg/kg). A total of 198 patients  were  randomized  and included  in the intent- 
to-treat (ITT) population, with 67 patients randomized to receive crizanlizumab at 5.0 mg/kg 
(5.0 mg/kg treatment arm), 66 patients to receive crizanlizumab at 2.5 mg/kg (2.5 mg/kg 
treatment arm), and 65 patients to receive placebo (placebo treatment arm).  
The primary efficacy parameter was the assessment of the annual rate of VOC leading to a healthcare visit, defined as an acute epi[INVESTIGATOR_212787], for which there is with no other medically 
determined explanation cause than a vaso -occlusive event, which requires a medical facility 
(clinic,  emergency  room (ER),  or hospi[INVESTIGATOR_307]) visit and treatment  with  oral or parenteral  narcotics, 
or parenteral non -steroidal anti- inflammatory drugs. Acute chest syndrome, hepatic 
sequestration, splenic sequestration and pr iapi[INVESTIGATOR_661844] a visit to a medical facility  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 23
0 Protocol No. 
  
 
were also considered VOC leading to a healthcare visit for analysis purposes. It was observed 
that treatment with 5.0 mg/kg crizanlizumab resulted in an annual rate of VOC leading to a 
healthcare visit that was 45.3% lower than the rate with placebo which was statistically significant (p = 0.010). The annual rate of VOC leading to a healthcare visit in the 2.5 mg/kg crizanlizumab treatment arm was compared with that of placebo, and although favorable (32.6% reduction with active treatment), it was not statistically significant (p = 0.180). In addition, in 
the 5.0 mg/kg crizanlizumab arm, numerical and clinically significant reductions in the annual rate of VOC leading to a healthcare visit were observed across important subgroups, including patients receivin g concomitant HU (32.1%) and not receiving concomitant HU (50.0%), and in 
patients with the HbSS genotype (34.6%) and non- HbSS genotype (50.5%) (HbSC, HbSβ0- 
thalassemia, HbSβ+-thalassemia, and others). The median annual rate of days hospi[INVESTIGATOR_661845] 5.0 mg/kg arm versus the placebo arm (4.00 versus 6.87, respectively); however this difference was not statistically significant. Treatment with crizanlizumab at 5.0 mg/kg was associated with longer median time to first VOC leading to  a 
healthcare visit compared with placebo (4.07 versus 1.38 months, p = 0.001) and median time  to second VOC leading to a healthcare visit compared to placebo (10.32 versus 5.09 months, p = 0.022). 
Crizanlizumab  was well  tolerated.  Adverse events  that occurred  in ≥5%  of patients  in an active 
dose group and were more than 2 times  higher than placebo  were:  arthralgia,  pruritus, vomiting, 
chest pain, diarrhea, fatigue, myalgia, musculoskeletal chest pain, abdominal pain, influenza 
and oropharyngeal pain. There were 5 deaths during the study (2 at 5.0 mg/kg, 1 at 2.5 mg/kg and 2 in the placebo group), and no deaths were deemed related to study drug. The proportion of subjects experiencing SAEs was 25.8% at 5.0 mg/kg, 32.8% at 2.5 mg/kg and 27.4% in the placebo group. Adverse events that occurred in 10% or more of the patients in either active treatment group and at a frequency that was at least twice as high as that in the placebo group were arthralgia  (5.0 mg/kg: 18.2% versus 2.5 mg/kg: 14.1% versus placebo: 8.1%), diarrhea  
(10.6% versus 7.8% versus 3.2%), pruritus (7.6% versus 10.9% versus 3.4%), vomiting (7.6% versus 10.9% versus 4.8%) and chest pain (1.5% versus 10.9% versus 1.6%). No patient developed anti -drug antibodies (ADA) against crizanlizumab during the course of the 
SUSTAIN study.  
A sub analysis of risk ratio (RR [95% confidence intervals]; p -value) of infections found no 
evidence  of association  between  crizanlizumab  and infections. For this analysis,  two subgroups 
were analyzed: infections and serious infections. The results show for infections a RR of 1.03 [0.82-1.29]: p=0.819; and  for serious infections a RR of 1.07 [0.58-1.97]: p=0.820. The  results 
suggest that the risk of infections and serious infections in crizanlizumab and placebo groups was similar.  
Overall, treatment of patients with SCD with crizanlizumab at 5.0 mg/kg showed positive clinical activity as demonstrated by a decrease in the annual VOC leading to a healthcare visit rate compared with placebo. Treatment with crizanlizumab at 5.0 mg/kg was also found to be well tolerated.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 24
0 Protocol No. 
  
 
2 Rationale  
2.1 Study rationale and purpose 
Clinical and toxicological studies performed to date for crizanlizumab were conducted using 
Reprixys material (SelG 1 mAb). To ensure supply of future clinical studies as well as 
commercial demand, [COMPANY_001] has optimized the production of crizanlizumab. The [COMPANY_001] 
material (SEG101 mAb) drug substance (DS) and drug product (DP) will be manufactured at [COMPANY_001] sites.  In vitro  characterization  and primate  PK experiments  conducted with both mAbs 
did not reveal  significant differences  that would influence PK/PD  results.  Therefore,  the change 
in cell line is not expected to impact the bioavailability or activity of the compound. The CSEG101A2202 study will be the first trial to administer crizanlizumab to SCD adult patients.  
The purpose of this study is to characterize the PK and PD of crizanlizumab  and to evaluate the 
safety and efficacy of crizanlizumab in SCD  patients.  
 
2.[ADDRESS_892776] 45 
patients  (to identify  27 evaluable patients)  will be enrolled to the treatment  group crizanlizumab  
5.0 mg/kg to complete full PK and PD sampling at week [ADDRESS_892777] 45 
patients are enrolled, 10 additional patients will be enrolled to the exploratory treatment group and begin at 7.5 mg/kg of crizanlizumab.  
The patients will undergo a screening period from Day - [ADDRESS_892778] 45 patients  will be enrolled  to 
receive infusion doses of crizanlizumab  5.0 mg/kg (test)  on the first day (Week  1 Day 1), Week 
3 Day 1, and then day 1 of every  4-week  cycle.  No dose reductions are allowed  in the study for 
patients assigned to 5.0 mg/kg dose. Patients will continue on study until [ADDRESS_892779] drug administration during which time blood samples for measurement of crizanlizumab will b e collected, and then after the fifth dose (Week 15 Day 1). Patients will be 
discharged from the study site on Day 2 of Week 1 and Day 2 of Week 15 and will return on Week  1 Day 4, Week  2 Day 1, Week  3 Day 1, Week  7 Day 1, Week  11 Day 1, Week  15 Day 1 
(patients to stay at study site for 24 hours as described above), Week 15 Day 4, Week 16 Day 1, Week 17 Day 1, Week 19 Day 1, and Day 1 of every 4 weeks for ambulatory visit for additional pharmacokinetic/pharmacodynamics and immunogenicity assessments and at [ADDRESS_892780] dose for the safety follow -up visit.  
After 45 patients are enrolled at the 5.0 mg/kg dose, up to 10 additional patients (to identify 6 evalua
ble patients) will be enrolled to the exploratory treatment group of 7.5 mg/kg 
crizan lizumab.  
The 10 patients will receive 
infusion doses of crizanlizumab at 7.5 mg/kg on the same schedule and with t he same  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 25
0 Protocol No. 
  
 
administration  requirements as for the 5.0 mg/kg group.  
 
  
 
 
2.3 Rationale for dose and regimen selection  
Patien ts will receive crizanlizumab  at a dose of 5.0 or 7.5 mg/kg by [CONTACT_93095] [ADDRESS_892781] dose to rapi[INVESTIGATOR_661846] -state serum concentrations. This is followed by [CONTACT_661887] 4- weeks ± 3 days to ensure that steady -state serum concentrations of 
crizanlizumab are maintained to provide a consistent blockade of P -selectin throughout the 
study. 
The SUSTAIN  trial tested  either  5.0 mg/kg or 2.5 mg/kg of SelG1  on this same dosing schedule 
and showed a statistically significant reduction in median annual rate of VOC leading to a 
healthcare visit in the 5.0 mg/kg dose group versus placebo, while the 2.5 mg/kg group did not have a statistically  significant reduction. The overall safet y was well-balanced  across  treatment 
and placebo  groups (5.0 mg/kg: 86% AE  and 26% SAE  – 2.5 mg/kg: 88% AE and 33% SAE  – 
placebo:  89% AE and 27% SAE)  (Ataga 2016).  The doses chosen  for the SUSTAIN study were 
based on complete P -selectin inhibition of SelG1 in healthy subjects, as well as the acceptable 
safety experience observed with 5.0 mg/kg and 8.0 mg/kg dosing regimens during the Phase I safety study. As mentioned in Sect ion [IP_ADDRESS], the phase I study (CSEG101A2101) found that 
a single dose of SelG1 at 5.0 mg/kg yielded at least 28 days of complete P- selectin  inhibition. 
 
 
 
2.4 Rationale for choice of combination 
Not applicable.  
 
2.5 Rationale for choice of comparators drugs 
Not applicable 
 
2.6 Risks and  benefits 
Overall, treatment of SCD patients with crizanlizumab at 5.0 mg/kg demonstrated statistically significant,  clinically  meaningful, and robust efficacy  results  vs. placebo  in reduction of annual 
rate of sickle cell -related pain crisis (SCPC) (also known as V OC leading to a healthcare visit) 
and delay of onset of VOC leading to a healthcare visit in a well -controlled Phase II clinical 
trial (SUSTAIN study) in a clearly defined SCD patient population. Treatment with crizanlizumab at 5.0 mg/kg was also found to be well tolerated   
 The substantial efficacy  and acceptable safety 
of crizanlizumab sugg est an overall favorable benefit -risk assessment and warrant further 
clinical development in  SCD.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 26
0 Protocol No. 
  
 
Crizanlizumab  was well tolerated  in SUSTAIN  study. There were no unexpected  safety  findings; 
however, infusion-related reactions were observed in around 2% of subjects. 
The risk of infections and serious infections with the use of crizanlizumab has been evaluated 
and the results suggest that the risk of infections and serious infections in crizanlizumab and placebo groups was similar. 
Monoclonal antibodies (mAbs) are large molecules intended to bind to specific targets often 
expressed on the immune system, and to treat various immunopathological conditions. Therefore, mAbs can be considered to have a high potential for immunotoxicity, which is reflected in the clinical experience accumulated on mAbs -induced adverse effects related to 
immunosuppression, immunostimulation and hypersensitivity (immunogenicity) (Descotes J, 2009). So far, clinical studies have shown no deleterious effects of the use of crizanlizumab in regards to immunotoxicity and immunogenicity. 
Appropriate eligibility criteria and stoppi[INVESTIGATOR_49315]. Recommended 
guidelines for prophylactic or suppor tive management  of study-drug induced adverse  events  are 
provided in Section  6.4. The risk to subjects  in this trial may be minimized  by [CONTACT_661888], as well as, close clinical monitoring, and in-patient 
status  for [ADDRESS_892782] Investigator’s Brochure. 
 
3 Objectives and  endp oints  
Objectives and related endpoints are described in Table 3 -1 below. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 27
7 Protocol No. 
  
 
 
Table 3-1 Objectives and related  endpoints  
Objective  Endpoint Analysis  
Primary  Refer to Section  10.4 
Characterize PK of crizanlizumab at 5.0 mg/kg 
in SCD patients  
Characterize PD (P -selectin inhibition) of 
crizanlizumab at 5.0 mg/kg in SCD patients  -PK parameters after the starting dose and after multiple doses.  
-Pre-dose concentrations prior to each study drug dose.  
-%P-selectin inhibition and PD -AUC after the starting dose, after multiple 
doses, and prior to each study drug dose.  
Secondary  Refer to Section  10.5 
Assess efficacy of crizanlizumab  -Annualized rate of VOC events leading to healthcare visit  in 
clinic/ER/hospi[INVESTIGATOR_307]  
-Annualized rate of VOC events treated at home (based on documentation 
by [CONTACT_661889])  
-Annualized rate of hospi[INVESTIGATOR_510727] (both total and VOC - 
related)  
-Annualized days of ER/hospi[INVESTIGATOR_059] (both total and VOC -related)  
-Annualized rate of each subcategory of VOC event (uncomplicated pain 
crisis, acute chest syndrome, hepatic sequestration, splenic sequestration, priapi[INVESTIGATOR_8801])  
-Annualized rate of VOC events (including both healthcare visit and home 
treatment)  
Assess safety and tolerability  of crizanlizumab  - Number, seriousness, severity, and causality assessments of  treatment  
emergent adverse events and other safety data as considered appropriate  
-Absolute change from baseline in hemoglobin  
-Immunogenicity: measurement of anti- drug antibodies (ADA) to 
crizanlizumab  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 28
7 Protocol No. 
  
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 29
9 Protocol No. 
  
 
 
4 Study design  
4.1 Description of study design  
This is a multicenter, single -arm, open -label study to assess PK and PD of crizanlizumab in 
adult patients with SCD and VOC. 
Approximately 55 patients  will be enrolled  in the trial. 45 eligible  patients  (all screening  criteria 
met) will be treated with crizanlizumab at a dose of 5.0 mg/kg and up to 10 additional eligible 
patients (all screening criteria met) will be treated with crizanlizumab at a dose of 7.5  mg/kg. 
The study will inclu de adult patients, ages 16- 70 years, with confirmed diagnosis of SCD 
(genotypes HbSS, HbSC, HbS β0-thalassemia, HbS β+-thalassemia, and others) who have 
experienced at least 1 VOC within the preceding 12 months. Patients may not plan to initiate 
HU/HC duri ng the study. For patients who are already treated with HU/HC, they should be 
taking HU/HC for at least [ADDRESS_892783] dosing. Patients continuing to receive benefit, defined as no evidence of increased frequency of VOCs and no severe adverse events attributed to drug as per Investigator’s assessment, will remain on study until crizanlizumab is commercially available or until patients are rolled over in a different crizanlizumab study or access program. 
 
Screening phase  
Within  [ADDRESS_892784] be performed during the 
screening period (day-35 to day- 1). 
 
Treatment phase  
Once eligibility  criteria have been  confirmed  to [COMPANY_001] via the eligibility  checklist,  the patient 
will be enrolled  in the trial and will receive crizanlizumab.  Study treatment  should be started  as 
soon as possible. 
Patients may be admitted to the study site prior to dosing for baseline evaluations. The first 45 
patients will receive crizanlizumab 5.0 mg/kg by [CONTACT_12781] 30 min on week 1 day 1, week 3 day 1, and then day 1 of every 4- week cycle. No dose change or modification will be 
allowed in the study for patients assigned to 5.0 mg/kg dose. Once [ADDRESS_892785] evaluable PK/PD data (or a total of 45 patients are enrolled) at the 5.0 mg/kg dose, an exploratory cohort of 10 patients will be enrolled at a dose of 7.5 mg/kg. Patients will receive crizanlizumab 7.5 mg/kg by [CONTACT_12781] [ADDRESS_892786] PK/PD sampling performed in order to characterize the PK/PD of crizanlizumab  (see Table  7-5).  On week  [ADDRESS_892787] dose in order to complete  the PK/PD  sample 
collection.  
In case of VOC, the related medical and treatment information will be collected.  
 
 
Safety will be monitored as outlined in Section [ADDRESS_892788] -treatment follow -up phase  
After the end of treatment visit, all patients will be followed up for safety up to 105 days (15 weeks) after the last dose of study treatment.  
 
Figure 4 -1 Study Design  
 
  
 
4.2 Timing of interim analyses and design adaptations 
Exploration of early  access  (EA) PK data may occur for preliminary  PK analysis  prior to clinical 
data base lock. PK samples  may be batched  and shipped for expedited  EA PK analysis  and data 
will be uploaded by [CONTACT_661890]. For the derivation of PK parameters nominal time instead of actual elapsed time may be  used. 
An interim analysis may be performed when there are at least 27 patients with single dose evaluable PK profiles  and approximately 5 patients with both single dose and multiple dose 
evaluable PK profiles in the 5.0 mg/kg treatment group in the Pharmacokinetic Analysis Set 1 (PAS1).  This interim analysis  may further characterize the PK/PD  profile  for the pediatric  study 
CSEG101B2201; however there is currently no plan for design adaptation of trial CSEG101A2202. Another interim analysis  may be performed  when  there  are approximately 15 
patients  with multiple  dose evaluable PK profiles  in the 5.0 mg/kg treatment  group in the PAS1, 
in order to inform the PK/PD/safety profile of crizanlizumab and potentially support the regulatory filing.  Should the criteria  for the two interim analyses  be reached  at similar  times  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 31
9 Protocol No. 
  
 
compatible with both objectives, a single combined interim analysis will be performed. 
Additional earlier or later ad hoc interim analyses of PK/PD/safety may be performed in order 
to support potential Health Authority requests. 
 
4.[ADDRESS_892789] 
27 patients  in the 5.0 mg/kg treatment  group in the Pharmacokinetic Analysis Set 1 (PAS1)  and 
Pharmacodynamics Analysis Set 1 (PDS1) respectively. The primary analysis data will be summarized in the primary clinical study report (CSR).  
Following the cut -off date for the analysis reported in the primary CSR, the study will remain 
open. Ongoing patients will continue to receive study treatment and be followed as per the schedule of assessments,  as long as patients  derive benefit  from  crizanlizumab. The end of study 
is defined by [CONTACT_661891]: 
• All patients have died or discontinued from the study 
• Crizanlizumab is commercially available for this patient population, and patients obtain the commercial  drug 
• Another clinical study becomes available that can continue to provide crizanlizumab in this patient population and all patients ongoing are transfe rred to that clinical study  
The final analysis will occur at the end of the study. All available data from all patients up to the trial end will be analyzed and summarized in a final CSR . 
 
4.[ADDRESS_892790] occur if one or more of the following reasons apply: 
• Decision of the Sponsor 
• Safety issues: If more than 25% of the subjects at any time point have been withdrawn due 
to adverse events or abnormal laboratory results and abnormal test proc edure results 
related to the study drugs. 
• If information becomes available that the use of crizanlizumab would expose the subjects 
to an unacceptable risk. 
In the event the safety stoppi[INVESTIGATOR_23893], the Sponsor and Principal Investigator [INVESTIGATOR_661847]. 
The investigator may be informed of additional procedures to be followed in order to ensure 
that adequate  conside ration  is given to the protection of the patient’s  interests.  The investigator 
will be responsible for informing IRBs and/or ECs of the early termination of the trial. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 32
9 Protocol No. 
  
 
5 Population 
5.1 Patient population 
CSEG101A2202 will enroll up to 55 SCD patients (any genotype) ages 16- [ADDRESS_892791] 1 VOC over the preceding 12 months, and who are not planning to take 
HU/HC during the trial or who have been taking HU/HC for at least [ADDRESS_892792] to meet all of the following criteria:  
1. Male or female, 16 to 70 years of age (inclusive) on the day of informed consent signature. 
2. Confirmed diagnosis of sickle cell disease by [CONTACT_661892]- 
performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease 
genotypes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others), though genotypi[INVESTIGATOR_661848]. 
3. Experienced at least 1 VOC within the preceding 12 months prior to Screening as 
determined by [CONTACT_9870]. Prior VOC should include the occurrence of appropriate 
symptoms, a visit to a medical facility and/or healthcare professional, and receipt of parenteral opi[INVESTIGATOR_661849]. 
4. If receiving  HU/HC  or erythropoietin stimulating  agent,  must have been  receiving  the drug 
for at least [ADDRESS_892793] meet the following laboratory values at the screening  visit:  
• Absolute Neutrophil Count ≥1.0 x 10
9/L 
• Platelets ≥75 x 109/L 
• Hemoglobin (Hgb) ≥4.0 g/dL  
• Glomerular filtration rate ≥ 45 mL/min/1.73 m2 using CKD- EPI [INVESTIGATOR_14420]  
• Direct (conjugated) bilirubin ≤2.[ADDRESS_892794] 
• Alanine transaminase (ALT) ≤ 3.[ADDRESS_892795]  
6. ECOG performance status  ≤[ADDRESS_892796] not meet any of the following criteria: 
1. History of stem cell transplant. 
2. Acute vaso -occlusive crisis ending within 7 days prior to Week 1 Day 1 dosing. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 33
9 Protocol No. 
  
 
3. Received blood products within 30 days of Week 1 Day 1 dosing. 
4. Participating in a chronic transfusion program (pre -planned series of transfusions  for 
prophylactic purposes). 
5. Planning on undergoing an exchange transfusion during the duration of the study; epi[INVESTIGATOR_661850] -occlusive crisis is  permitted.  
6. Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipi[INVESTIGATOR_215176]. 
7. History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opi[INVESTIGATOR_638570].  
8. Use of therapeutic anticoagulation (prophylactic doses permitted) or antiplatelet therapy (other than aspi[INVESTIGATOR_49267]) within the 10 days prior to W eek 1 Day 1  dosing 
9. Received a monoclonal antibody or immunomodulatory agent within 1 year of Screening, or has documented immunogenicity to a prior biologic 
10. Received active treatment on another investigational trial within 30 days (or 5 half -lives of 
that agent, whichever is  greater) prior to Screening or plans to participate in another 
investigational drug trial 
11. Pregnant or nursing women  
12. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless  they are using highly effective methods of contraception  during 
dosing and for 15 weeks after stoppi[INVESTIGATOR_056]. Highly effective contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception  
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104]  
• Male sterilization (at least 6 months prior to screening). The vasectom ized male 
partner should be the sole partner for that subject  
• Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have  comparable efficacy (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception. 
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of 3 months before taking study treatment. 
13. Current drug or alcohol abuse:  
• Has a positive qualitative urine drug test at Screening for cocaine, phencyclidine 
(PCP), or amphetamines  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 34
9 Protocol No. 
  
 
• Consumes >12 (for males) or >8 (for females) standard alcoholic beverages per week  
14. Any documented history of a clinical  stroke or intracranial  hemorrhage,  or an uninvestigated 
neurologic finding within the past [ADDRESS_892797] only present 
on imaging is allowed.  
15. Patients with bleeding  disorders 
16. Planning to undergo a major surgical procedure during the duration of the study 
17. Hospi[INVESTIGATOR_057] a t Screening  
18. Poorly-controlled HIV infection (CD4 count <200 cells/mm3 or viral load >50 copi[INVESTIGATOR_014]/mL)  
19. Patients with active Hepatitis B infection (HBsAg positive) will be  excluded 
• Note: Patients with antecedent but no active Hepatitis B (i.e. anti-HBc positive , 
HBsAg and HBV- DNA negative) are eligible  
20. Patients with positive test for hepatitis C ribonucleic acid (HCV  RNA)  
• Note: Patients in whom HCV infection resolved spontaneously (positive HCV 
antibodies without detectable HCV- RNA) or those that achieved a sustained 
virological response after antiviral treatment and show absence of detectable HCV RNA ≥ 6 months (with  the use of IFN -free regimes)  or ≥ 12 months (with  the use of 
IFN-based regimes) after cessation of antiviral treatment are eligible  
21. Significant active  infection  or immune  deficiency  (including chronic use of 
immunosuppressive drugs) 
22. Malignant disease. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers and any completely  
resected carcinoma in  situ 
23. Has a serious mental or physical illness, which, in the opi[INVESTIGATOR_661851]  
24. Any condition which, in the opi[INVESTIGATOR_871], is likely to interfere with the successful collection of the measurements required for the study. 
25. Resting QTcF ≥470 msec at pretreatment  (baseline)  
26. Cardiac or cardiac repolarization abnormality, including any of the following: 
• History of myocardial infarction (MI), angina pectoris, coronary artery by[CONTACT_9292] (CABG), or uncontrolled congestive heart failure within 6 months prior to starting study treatment  
• Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) 
• Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: 
• Risk factors for Torsade de Pointes (TdP) including uncorrected hypokalemia or 
hypomagnesemia, history of cardiac failure, or history of cl inically 
significant/symptomatic  bradycardia 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 35
9 Protocol No. 
  
 
• Concomitant medication(s) with a “Known risk of Torsade de Pointes” per 
wwwqtdrugsorg that cannot be discontinued or replaced by [CONTACT_64077] (within 5 half- lives prior to starting study drug) 
• Inability to determine the QTcF  interval 
27. Not able to understand and to comply with study instructions and requirements.  
 
6 Treatment  
6.1 Study treatment  
[COMPANY_001] will supply crizanlizumab  (SEG101) as an open label  medication.  The investigational 
drug will be the crizanlizumab - SEG101 Histidine/Citrate buffered solution – provided every 
[ADDRESS_892798] dosing (i.e. dosing on first day of week1, week3, week7, and then every 4 weeks) until the end of study. 
 
6.1.1  Dosing regimen  
 
Table 6-1 Dose and treatment  schedule  
Study  treatments  Pharmaceutical  form  
and route of 
administration  Dose  Frequency and/or 
Regimen  
 
SEG101  Intravenous  infusion  5.0 mg/kg or  7.5 mg/kg  Week 1 Day 1, Week  3 
Day   1,   Week  7 
Day 1 and day 1 of 
every 4-week 
cycle  
 
Crizanlizumab  is provided in single use vials  containing 10 mL at a concentration  of 10 mg/mL. 
The crizanlizumab formulation is a Histidine/Citrate buffered solution which is supplied in single use vials at a concentration of 10 mg/mL.  
Each  patient  receives  one dose of crizanlizumab  on Week  [ADDRESS_892799] or designated personnel 
will compound individual doses of crizanlizumab  for patients  on a milligram per kilogram basis 
in a 100 mL infusion bag of a sterile 0.9% sodium chloride solution (0.9% Sodium Chloride Injection, USP)  in accordance with the Pharmacy  Manual.  Study drug will be administered  over 
[ADDRESS_892800] shelf -life, crizanlizumab  Histidine/Citrate  buffered  solution may be substitute 
by [CONTACT_661893] (FMI), citrate buffered solution. Minor modifications in the final buffer com position are expected and will be covered by [INVESTIGATOR_2993]- vitro comparability  studies. 
 
6.1.2  Ancillary  treatments  
Not applicable.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 36
9 Protocol No. 
  
 
6.1.3  Rescue medication  
Not applicable.  
 
6.1.4  Guidelines for continuation of  treatment  
For guidelines for continuation of treatment, refer to Section 6.3 Dose modifications. 
Patients  who permanently  discontinue the study drug for any reason  should follow the protocol 
safety assessments as scheduled. After discontinuing study treatment, further treatment is left 
to the physician’s discretion. 
 
6.1.[ADDRESS_892801] occurrence of one of the following (see Section 7.1.4):  
• All patients have died or discontinued from the study 
• Crizanlizumab is commercially available for this patient population, and patients are eligible to be prescribed the commercial  drug 
• Another clinical study becomes available that can continue to provide crizanlizumab in this patient population and all patients ongoing are eligible to be transferred to that clinical study 
 
6.2 Dose escalation  guidelines 
Not applicable 
 
6.3 Dose modifications 
6.3.1  Dose modification and dose  delay 
For patients who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow patients to continue the study treatment until the next dose scheduled. Dose reductions are o nly allowed for 
patients assigned to 7.5 mg/kg dose . No dose reductions are allowed in the study for 
patients assigned to 5.0 mg/kg dose who just have option for dose interruption. The dose reduction is only in one level:  from  7.5 mg/kg to 5.0 mg/kg and it is recommended  at the grade 
[ADDRESS_892802] to be done at the next dose scheduled. 
These dose interruptions / reductions are summarized in Table 6 -4. Deviations to mandatory 
dose interruptions are not allowed. Permanent treatment discontinuation is mandatory for 
specific events indicated as such in Table 6 -4 or listed in Section [IP_ADDRESS]. 
Missing 2 consecutive doses (no dose for 10 weeks) would be considered criteria for permanently discontinuing the patient from the study. 
Any dose changes must be recorded on the Dosage Administration Record CRF. 

[COMPANY_001]  
Amended Protocol Versi on 01 Clean  Confidential  Page 37
7 Protocol No. 
  
 
 
Table 6-2 Criteria for dose reduction / interruption and re- initiation of crizanlizumab treatment for adverse drug  reactions.  
 
 
Dose modifications for crizanlizumab  
Worst toxicity  
CTCAEa Grade (value) during a cycle of therapy   
Investigations (Hematologic)  
Neutropenia (ANC)  
Grade 1 (ANC < LLN - 1500/mm3) Recommendation: maintain dose level  
Grade 2 (ANC < 1500 - 1000/mm3) Recommendation: maintain dose level  
Grade 3 (ANC < 1000 - 500/mm3) - Recommendation: interrupt dose until resolved to ≤ Grade 2 or next dose scheduled.  If 
abnormality persists permanently discontinue the patient from the  study.  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5 mg/kg. If after the 
reducti on of dose the abnormality improves to ≤ Grade 2 re -escalation to 7.5 mg is  allowed.  
Grade 4 (ANC < 500/mm3) Mandatory : Interrupt dose until resolved to ≤ Grade 2 or next dose scheduled. If abnormality 
persists permanently discontinue the patient from the study.  
Febrile neutropenia (ANC < 1.0 x 109/L, fever ≥ 
38.3°C)  
A disorder characterized by [CONTACT_217779] <1000/mm3 
and a single temperature of >38.3 degrees C (101 
degrees F) or a sustained temperature of ≥38 
degrees C  Mandatory : Interrupt dose until resolved or next dose schedule. If abnormality persists 
permanently discontinue the patient from the study.  
Thrombocytopenia  
Grade 1 (PLT < LLN - 75,000/mm3) May maintain dose level  
Grade 2 (PLT < 75,000 - 50,000/mm3) May maintain dose level  
Grade 3 (PLT < 50,000 - 25,000/mm3) - Recommendation: interrupt dose until resolved to ≤ Grade 1 or next dose scheduled. If 
abnormality persists permanently discontinue the patient from the study, then:  
- If resolved in ≤ [ADDRESS_892803] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
 - If resolved in > 7 days, then ↓ 1 dose level (for 7.5 mg/kg dosed patients only: reduction to  
5 mg/kg dose). If after the reduction of dose the abnormality improves to ≤ Grade 2 re- 
escalation to 7.5 mg is allow ed. 
Grade 4 (PLT < 25,000/mm3) Mandatory : Interrupt dose until resolved to ≤ Grade 1 or next dose scheduled. If abnormality 
persists permanently discontinue the patient from the study.  
Investigations (Renal)  
Serum creatinine  
Grade 1 (>1.0 – 1.5 x baseline OR > ULN - 1.[ADDRESS_892804])  May maintain dose level  
Grade 2 (> 1.5 – 3.0 x baseline OR > 1.[ADDRESS_892805])  - Recommendation: interrupt dose until resolved to ≤ Grade 1 or baseline level or next  dose 
scheduled. If abnormality persists permanently discontinue the patient from the study.  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5 mg/kg. If after the 
reduction of dose the abnormality improves to ≤ Grade 1 re -escalation to 7.5 mg is  allowed.  
Grade 3 (> 3.0 x baseline OR > 3.[ADDRESS_892806])  - Recommendation: interrupt dose until resolved to ≤ Grade 1 or baseline level or next dose 
scheduled. If abnormality persists permanently discontinue patient from study drug treatment.  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5 mg/kg. If after the 
reduction of dose the abnormality improves to ≤ Grade 1 re -escalation to 7.5 mg is  allowed.  
Grade 4 (> 6.[ADDRESS_892807])  - Mandatory : interrupt dose until resolved to ≤ Grade 1 or baseline level or next dose 
scheduled. If abnormality persists permanently discontinue the patient from the study.  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5 mg/kg. If after the 
reduction of dose the abnormality improves to ≤ Grade 1 re -escalation to 7.5 mg is  allowed.  
Investigations (Hepatic)  
Isolated total Bilirubin elevation  
Grade 1 (> 1.[ADDRESS_892808])  Recommendation: maintain dose level  

[COMPANY_001]  
Amended Protocol Versi on [ADDRESS_892809] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
Grade 2 (> 1.5 – 3.[ADDRESS_892810])  Recommendation: maintain dose level  
Grade 3 (> 3.[ADDRESS_892811]*)  - Recommendation:  
- Interrupt dose. Monitor LFTsb weekly, or more frequently if clinically indicated, until resolved 
to ≤ 1.[ADDRESS_892812].  
- Monitor for  hemolysis  
- If resolved, then continue with next dose scheduled  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5 mg/kg after 
confirmation of no hemolysis. If after the reduction of dose the abnormality improves to ≤  Grade 
2 re-escalation to 7.5 mg is  allowed.  
Grade 4 (> 10.[ADDRESS_892813]*)  - Mandatory : 
- Interrupt dose. Monitor LFTsb weekly, or more frequently if clinically indicated, until resolved 
to ≤ 1.[ADDRESS_892814].  
- Monitor for  hemolysis  
- If resolved, then continue with next dose scheduled  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5.0 mg/kg after 
confirmation of no hemolysis. If after the reduction of dose the abnormality improves to ≤  Grade 
1 re-escalation to 7.5 mg is  allowed.  
 
- If abnormality persists permanently discontinue patient from study drug treatment. 
- The patient should be monitored weekly (including LFTsb), or more frequently if  clinically 
indicated, until total bilirubin have resolved to baseline or stabilization over [ADDRESS_892815] or ALT elevation  
Grade 1 (> ULN - 3.[ADDRESS_892816])  Recommendation: maintain dose level  
Grade 2 (> 3.[ADDRESS_892817])    
 

[COMPANY_001]  
Amended Protocol Versi on [ADDRESS_892818] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
- For patients with baseline value ≤ 3.[ADDRESS_892819] 
 
 
 
 
- For patients with baseline value > 3.[ADDRESS_892820] - Recommendation: maintain dose level. Repeat LFTsb as soon as possible, preferably within 
48-72 hours from awareness of the abnormal results; if abnormal lab values are confirmed  upon 
the repeat test, then monitor LFTsb weekly, or more frequently if clinically indicated, until 
resolved to ≤ 3.[ADDRESS_892821] 
 
- Maintain dose level  
Grade 3 (> 5.[ADDRESS_892822])  
- For patients with baseline value ≤ 3.[ADDRESS_892823] 
 
 
 
 
- For patients with baseline value > 3.[ADDRESS_892824]  
- Recommendation: interrupt dose. Repeat LFTsb as soon as possible, preferably within 48- 72 
hours from awareness of the abnormal results; monitor LFTsb weekly, or more frequently if 
clinically indicated, until resolved to ≤ 3.[ADDRESS_892825]  Then  
If resolved, maintain dose level  
 
- Maintain dose level. Repeat LFTsb as soon as possible, preferably within 48- 72 hours from 
awareness of the abnormal results; if abnormal lab values are confirmed upon the repeat  test, 
then monitor LFTsb, weekly, or more frequently if clinically indicated, until resolved to ≤ 5.[ADDRESS_892826]  
Grade 4 (> 20.[ADDRESS_892827])  - Recommendation: interrupt dose. Repeat LFTsb as soon as possible, preferably within 48- 72 
hours from awareness of the abnormal results; monitor LFTsb weekly, or more frequently if 
clinically indicated, until resolved to ≤ [ADDRESS_892828] (or ≤ [ADDRESS_892829] for patients with baseline value > 
3.0-5.[ADDRESS_892830]), if reoccurs at > [ADDRESS_892831], permanently discontinue patient from study drug 
treatment.  
- Recommendation for 7.5 mg/kg dosed patients only : ↓ 1 dose level to 5.0 mg/kg. If after the 
reduction of dose the abnormality improves to ≤ Grade [ADDRESS_892832] or ALT and bilirubin (direct [conjugated] and/or total)  
For patients with normal baseline ALT and AST and (direct or total) bilirubin value:  Mandatory : 
- Monitor for hemolysis.  
 

[COMPANY_001]  
Amended Protocol Versi on [ADDRESS_892833] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
• AST or ALT >3.0xULN combined with 
direct or total bilirubin >2.[ADDRESS_892834]  without 
evidence of  cholestasis  
 
 
OR (Note to study team: If supported by [CONTACT_339583])  
 
For patients with elevated baseline AST or ALT or direct or total bilirubin value:  
• AST or ALT>2x baseline AND > 3.[ADDRESS_892835] 
OR 
• AST or ALT > 8.[ADDRESS_892836], combined with 
[direct or total bilirubin >2x baseline 
AND >2.[ADDRESS_892837]]  - If elevations of ALT and/or AST (>3.[ADDRESS_892838]) and direct or total bilirubin (>2.[ADDRESS_892839]) 
without evidence of cholestasisd (ALKP < [ADDRESS_892840]) are observed simultaneously at the  
visit: interrupt dose and monitor for hemolysis. If abnormality persists without evidence of hemolysis, permanently discontinue patient from study drug treatment.  
 
Recommendation: If elevations of direct or total bilirubin precede the elevations of ALT and or AST, monito r for hemolysis.  
 
Repeat as soon as possible, preferably within [ADDRESS_892841] resolved to baseline or stabilization over 4 weeks. Refer to Section [IP_ADDRESS] for 
additional follow -up evaluations as applicable.  
Investigation (metabolic)  
Asymptomatic amylase and/or lipase elevation  
Grade 1 (> ULN - 1.[ADDRESS_892842])  May maintain dose level  
Grade 2 (> 1.[ADDRESS_892843])  May maintain dose level  
Grade 3 (> 2.[ADDRESS_892844])  Recommendation: interrupt dose until resolved to Grade ≤1 or baseline then:  
- If resolved, then maintain dose level 
- If resolved in > 7 days, then ↓ 1 dose level (for 7.5 mg/kg dosed patients only: reduction to 
5 mg/kg dose). If after the reduction of dose the abnormality improves to ≤ Grade 2 re- 
escalation to 7.5 mg is  allowed.  
Grade 4 (> 5.[ADDRESS_892845])  Mandatory : interrupt dose until resolved to ≤ Grade [ADDRESS_892846] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
Gastro intestinal  
Pancreatitis  
Grade 2 (Enzyme elevation or radiologic findings 
only)  Recommendation : maintain dose level  
Grade ≥ 3 - Severe pain; vomiting; medical 
intervention indicated (e.g., analgesia, nutritional  
support)  Mandatory : interrupt dose and permanently discontinue patient from study drug treatment  
Diarrhea***  
Grade 1 (Increase of <4 stools per day over 
baseline)  May maintain dose level but, initiate anti- diarrhea treatment  
Grade 2 (Increase of 4 - 6 stools per day over 
baseline)  Recommendation:  
- Interrupt dose until resolved to ≤ grade 1, then maintain dose level.  
- If diarrhea returns as ≥ grade 2, then interrupt dose until resolved to ≤ grade  1. 
Grade 3 (Increase of >=7 stools per day over 
baseline; incontinence; hospi[INVESTIGATOR_374])  Recommendation: interrupt dose and permanently discontinue patient from study drug treatment  
Grade 4 (Life- threatening consequences; urgent 
intervention indicated)  Mandatory : interrupt dose and permanently discontinue patient from study drug treatment  
Skin and subcutaneous tissue disorders  
Rash/photosensitivity  
Grade 1 - Macules/papules covering <10% Body 
Surface Area (BSA) with or without symptoms (e.g., 
pruritus, burning, tightness)  May maintain dose level. Consider to initiate institute appropriate skin toxicity therapy (such as 
antihistamines, topi[INVESTIGATOR_63951] -dose systemic corticosteroids)  
Grade 2 - Macules/papules covering 10 - 30% BSA  
with or without symptoms (e.g., pruritus, burning, 
tightness)  May maintain dose level, but initiate/intensify appropriate skin toxicity therapy (such as 
antihistamines, topi[INVESTIGATOR_63951] -dose systemic corticosteroids)  

[COMPANY_001]  
Amended Protocol Versi on [ADDRESS_892847] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
Grade 3, despi[INVESTIGATOR_252370] - 
Macules/papules covering >30% BSA with or 
without associated symptoms  Recommendation:  
- Interrupt dose until resolved to Grade ≤ 1,  then:  
- If not resolved (despi[INVESTIGATOR_11932]), then permanently  discontinue 
patient from study drug  treatment  
Grade 4, despi[INVESTIGATOR_661852] : interrupt dose and permanently discontinue patient from study drug treatment  
Fatigue (General disorders and administration site conditions). A disorder characterized by a state of generalized weakness with a pronounced 
inability to summon sufficient energy to accomplish daily activities.  
Grade 1 (Fatigue relieved by [CONTACT_9075])  May maintain dose level  
Grade 2 (Fatigue not relieved by [CONTACT_9075])  May maintain dose level  
Grade 3 (Fatigue not relieved by [CONTACT_9075], limiting self - 
care Activities of Daily Living)  Recommendation:  
- Interrupt dose until resolved to ≤ grade 1, then  : 
- If resolved, then maintain dose  level 
a Common Toxicity Criteria for Adverse Events (CTCAE Version 4.03)  
b Core LFTs consist of ALT, AST, GGT, total bilirubin (fractionated [direct and indirect], if total bilirubin > 2.[ADDRESS_892848]), and alkaline phosphatase 
(fractionated [quantification of isoforms], if alkaline phosphatase > 2.[ADDRESS_892849].)  
c “Combined” defined as total bilirubin increase to the defined threshold concurrently with ALT/AST increase to the defined threshold  
If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the instructions for isolated elevation of  total 
bilirubin and isolated elevation of AST/ALT, and take a conservative action based on the degree of the elevations (e.g. discontinue treatment at the situation when omit dose is needed for one parameter and discontinue treatment is required for another parameter). After all elevations resolve to the 
defined thresholds that allow treatment re- initiation, re- start the treatment either at the same dose or at one dose lower if meeting a criterion for dose 
reduction. Dose reductions are only allowed for patients assigned to 7.5 mg/kg dose. No dose reductions are allowed in the study for patients 
assigned to 5.0 mg/kg dose.  
d “Cholestasis” defined as ALP elevation (>2.[ADDRESS_892850] and R value <2 ) in patients without bone metastasis, or elevation of ALP liver fra ction in patients 
with bone metastasis  
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. It denotes whether the relative pattern of 
ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocell ular ( R ≥ 5), or mixed (R >2 and < 5) liver injury  

[COMPANY_001]  
Amended Protocol Versi on [ADDRESS_892851] toxicity  
CTCAEa Grade (value) during a cycle of therapy   
* Note: If total bilirubin > 3.[ADDRESS_892852] (non -conjugated) component only, and hemolysis as the etiology has been ruled out as per 
institutional guidelines (e.g., review of peripheral blood smear and haptoglobin determination), continue treatment at the discretion of the investigator.  
** Note: A CT scan or other imaging study to assess the pancreas, liver, and gallbladder must be performed within [ADDRESS_892853] occurrence of any  
≥ Grade 3 of amylase and/or lipase. If asymptomatic Gr ade 2 elevations of lipase and/or amylase occur again at the reduced dose, patients will be 
discontinued permanently from study treatment.  
*** Note: antidiarrheal medication is recommended at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt diar rhea 

[COMPANY_001]  
Amended Protocol Versio n 01 Clean  Confidential  Page 45
5 Protocol No. 
  
 
 
Table 6-3 Management for drug- related toxicities  
 
Toxicity  Management  
Infusion -related reactions  
Grade 1  Decrease infusion rate until recovery  
Grade 2  Stop infusion 
 
Before restarting - administer oral premedication (e.g.1000 mg of 
acetaminophen/paracetamol, 50- 100 mg diphenhydramine hydrochloride 
or alternative antihistamine), within 60 minutes of restarting the infusion.  
Restart infusion at 50% of previous rate under  continuous observation. 
Ensure that there is a minimum observation period of 1 hour prior to 
restarting the infusion(s).  
If the AE recurs at the reinitiated slow rate of infusion, and despi[INVESTIGATOR_632719]-medication, then discontinue patient from study.  
Grade 3 and 4  Discontinue study treatment  
 
[IP_ADDRESS]  Follow up on potential drug- induced liver injury (DILI)  cases  
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically important events. 
The threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL 
value; pati ents meeting any of the following criteria will require further follow -up as outlined 
below: 
• For patients with normal ALT and AST and TBIL value at baseline: AST or ALT > 3.[ADDRESS_892854] combined with TBIL > 2.[ADDRESS_892855]  
• For patients with elevated AST or ALT or TBI L value at baseline: [AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_892856]] OR [AST or ALT > 8.[ADDRESS_892857]], combined with [TBIL > 2 x 
baseline AND > 2.[ADDRESS_892858]]  
Medical review needs to ensure that liver test elevations are not caused by [CONTACT_15014], defined as ALP  elevation  > 2.[ADDRESS_892859] with R value < 2 in patients  without bone metastasis,  or elevation 
of ALP liver fraction in patients with bone metastasis.  
Monitoring for hemolysis in subjects  with elevations  of TBIL  > 2.[ADDRESS_892860] should be performed 
to rule out a plausible explanation of increase of TBIL.  
Note: (The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury).  
In the absence of cholestasis, these patients should be immediately discontinued from study drug treatment,  and repeat  LFT testing  as soon as possible, preferably  within  48 hours from  the 
awareness of the abnormal results. The evaluation should include laboratory tests, detailed history, physical assessment and the possibility of liver metastasis or new liver lesions, obstructions/compressions, etc. 

[COMPANY_001]  
Amended Protocol Versio n [ADDRESS_892861] bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 
2. A detailed  history, including relevant  information, such as review  of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any pre- existing liver 
conditions or risk factors, should be collected.  
3. Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary 
tract) may be warranted.  
4. Obtain PK sample, as close as possible to last dose of study drug. 
5. Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy may be considered as clinically indicated or after 
consultation wi th specialist/hepatologist.  
6. If elevations of total bilirubin precede the elevations of ALT and or AST, monitoring for 
hemolysis. 
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no other alternative cause for LFT abnormalities identified should be considered as “medically significant”,  thus, met the definition  of SAE  (Section  8.2.1) and reported  as SAE  using the term 
“potential  drug-induced liver injury”. All events  should be followed up with the outcome clearly 
documented. 
 
[IP_ADDRESS]  Dose adjustments for QTcF  prolongation  
In case of QTcF >500 msec, (or QTcF prolongation >60 msec from baseline) 
1. Assess the quality of the ECG recording and the QT value and repeat if needed 
2. Interrupt study treatment  
3. Determine the serum electrolyte levels (in particular hypokalemia, hypomagnesem ia). If 
abnormal, correct abnormalities before resuming study drug treatment.  
4. Review concomitant medication associated with QT prolongation, including drugs with a “Known”, “Possible”, or “Conditional risk of Torsades de Pointes ” and drugs with the 
potential to increase the risk of study drug exposure related QT prolongation (See  
Appendix 2) 
5. Check study drug dosing schedule and treatment compliance 
6. Consider collecting a time -matched PK sample and record time and date of last study  drug 
intake.  
After confirming ECG reading at site, if QTcF > 500 msec (or QTcF prolongation >60 msec from baseline)  
• Interrupt study treatment  
• Repeat ECG and confirm ECG diagnosis by a cardiologist or central ECG lab 
• If QTcF confirmed > 500  msec:  
• Correct electrolytes, eliminate culprit concomitant treatments, and identify and address clinical conditions that could potentially prolong the QT. 
• Cons ult with a cardiologist (or qualified  specialist)  
• Increase cardiac monitoring as indicated, until the QTcF returns to ≤ 480 msec.  

[COMPANY_001]  
Amended Protocol Versio n 01 Clean  Confidential  Page 47
5 Protocol No. 
  
 
• After resolution to ≤ 480 msec, consider re -introducing treatment at reduced dose (for 7.5 
mg/kg only), and increase ECG monitoring for the next treatment(s):  
• If QTcF remains ≤ 500 msec after dose reduction, continue planned ECG monitoring 
during subsequent treatment  
• If QTcF recurs > 500 msec after dose reduction, discontinue patient from trial. 
6.4 Concomitant medications 
In general, the use of any concomitant medication/therapi[INVESTIGATOR_661853]  (see Section  6.4.1),  except  as specifically  prohibited (see Section  6.4.2).  
The patient must be told to notify the investigational site about any new medications he/she takes within 30 days prior to initial dosing until the completion of end of study (EOS) visit (through [ADDRESS_892862] dose of study treatment).  All medications  (including prescription 
drugs, herbal  medications/supplements, over the counter  (OTC) medication,  dietary  and vitamin 
supplements) and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and blood 
transfusions) taken or administered within the timeframe defined in the entry criteria until 
completion  of the EOS  visit must be listed  on the Prior and Concomitant medications,  Surgical 
and Medical Procedures or Transfusion page of the CRF.  
 
6.4.1  Permitted concomitant therapy  
Concomitant sickle  cell therapy  with  hydroxyurea or hydroxycarbamide is  permitted,  provided 
the patient has been prescribed HU/HC consistently over at least the 6 months prior to 
enrollment, as stated in the Inclusion criteria. Erythropoietin- stimulating agents are also 
permitted  to manage chronic  symptomatic  anemia with the same requirement  for 6 months prior 
therapy as HU/HC. L -glutamine oral powder (Endari) is also permitted without restriction. 
Aspi[INVESTIGATOR_248], NSAIDs and prophylactic doses of anticoagulants are permitted, while other anti - 
platelets agents or anticoagulants at doses targeting therapeutic levels are prohibited. 
All FDA- approved forms of analgesia for pain are permitted per standard of care. Other 
approved medications for supportive care (antiemetics, anxiolytics, hypnotics, antihistamines) 
are permitted, including marinol. 
 
6.4.2  Permitted concomitant therapy requiring caution and/or  action  
Although transfusion of cellular  blood products is permitted,  it is unclear  how such transfusions 
will impact the PK and/or PD of crizanlizumab,  
 It should also be 
considered that the administration of products containing immunoglobulins (plasma, IVIG, anti-globulins) may also impact the efficacy of crizanlizumab, and optional PK and PD testing 
may also be performed prior to and following administration of such therapi[INVESTIGATOR_014].  
Although Endari, the FDA -approved, version of L -glutamine, is permitted, other over -the- 
counter forms of L -glutamine are discouraged, as are other natural and herbal remedies (e.g. 
EvenFlo and/or products containing dang gui, ligustrum root, ginseng root, white peony, corydalis, salvia,  copodonosis, poria, jujbe, angelica sinensis,  lovage)  due the unproven efficacy 
and variable quality  and composition of these products. Vitamin  and mineral  supplements (e.g. 
fish oil, folic acid,  L-arginine, L- citrulline,  magnesium,  riboflavin, vitamin  C, vitamin  D, 

[COMPANY_001]  
Amended Protocol Versio n 01 Clean  Confidential  Page 48
5 Protocol No. 
  
 
vitamin E, and Zinc) are also permitted, though caution is advised when taking amounts 
exceeding 100% of the recommended daily allowance. 
 
6.4.3  Prohibited concomitant  therapy  
As far as possible avoid co-administering drugs with a “Known”, “Possible”, or “Conditional” risk of Torsades de Pointes (TdP) as per wwwqtdrugsorg during the course of the study: 
• If concomitant administration of drugs with a “Known risk of Torsades de Pointes” is 
required and cannot be avoided, study drug must be interrupted. Study treatment may only be resumed after 5 half -lives (of the QT-prolonging drug) from last dose of the QT 
prolonging drug, and close ECG monitoring is advised. 
• If during the course of the study, concomitant administration of a drug with ¨Possible risk¨ or ¨Conditional risk of Torsades de Pointes¨ is required, based on the investigator assessment and clinical need, study treatment may be continued under close ECG monitoring to ensure patient safety.  
A list of drugs associated with QT prolongation and/or TdP is available online at wwwqtdrugsorg. 
The use of other investigational agents is prohibited during the study. In addition, the 
administration of monoclonal antibodies other than crizanlizumab is prohibited, due to the theoretical potential for cross -reactivity and/or overlappi[INVESTIGATOR_661854]. If investigational agents or other monoclonal antibodies have been used in the past, 
they must have been discontinued at least 30 days (or 5 half -lives of that agent, whichever is 
greater) prior to Screening. 
Infusion-type reactions  were rarely  reported  in prior studies with crizanlizumab,  so prophylaxis 
for such reactions  is not recommended.  If a patient  experiences  severe infusion- related  reaction, 
study drug should be discontinued and appropriate treatment provided. 
 
6.4.4  Use of Bisphosphonates (or other concomitant  agents)  
Not applicable 
 
6.[ADDRESS_892863] Number (Subject No.) (7 digits), that is 
assigned  when  the patient  is first enrolled  for screening  and is retained  as the primary  identifier 
for the patient throughout his/her entire participation in the trial. The Subject No. consists of the Center  Number (Center  No. 4 digits)  (as assigned  by [CONTACT_324406]) with 
a sequential patient number suffixed to it (3 digits), so that each patient is numbered uniquely across the entire database. Upon signing the informed consent form, the patient is assigned to the next sequential Subject No. available to the investigator through the Clinical Data Management System  interface.  

[COMPANY_001]  
Amended Protocol Versio n [ADDRESS_892864] 45 patients will be assigned to the 5.0 mg/kg crizanlizumab treatment, while the 10 
next enrolled patients will be assigned to the 7.5 mg/kg crizanlizumab treatment ( Section 4.1  
and Section 6.1 ). The assignment of a patient to a particular treatment dose will be confirmed 
by [CONTACT_661894]. 
 
6.5.[ADDRESS_892865]  of the treatment knowledge, until 
the primary analysis is conducted, no aggregated statistical analyses (efficacy or safety across the study) shall be performed by [CONTACT_3148] (other than analyses as specified in the study protocol). 
 
6.[ADDRESS_892866]  or study personnel appropriately  trained  in the 
preparation of liquids for parenteral administration (use aseptic techniques when preparing the study drug solution). Only compatible material tested during compatibility should be used for the administration of  crizanlizumab.  
Prior to administration, the crizanlizumab admixture should be allowed to warm to room temperature by [CONTACT_57741]. Do not heat thecrizanlizumab admixture in a microwave or with any heat source other than ambient air temperature. The crizanlizumab study drug product should only be administered via IV infusion including a 0.2μm inline filter and must be diluted prior to administration. 
NOTE: DO NOT ADMINISTER THE STUDY DRUG AS AN IV PUSH OR BOLUS  
INJECTION. After administration of study drug (5.0 mg/kg crizanlizumab or 7.5 mg/kg 
crizanlizumab),  a [ADDRESS_892867] 25 mL of sterile 0.9% sodium chloride solution (0.9% Sodium Chloride Injection, 
USP) for administration after that of study  drug. 
Prepared infusion solution in infusion bag should be used immediately, and must be within 4 hours of preparation. 
If the selected center for the clinical study is located in US and is USP<797> compliant, the 
preparation  and handling of the infusion bags shall comply with the guidance given in the USP 
but is limited to the physico -chemical stability demonstrated as indicated  below.  
If the selected center for the clinical study is located in US and is NOT USP<797> compliant, from a microbiologic point of view, the ready mixed infusion bag shall be used immediately and not be held for longer than four hours at room temperature from the moment the first vial is pi[INVESTIGATOR_661855].  
The compounded 0.9% sodium chloride (saline) bag with crizanlizumab should be intravenously administered  over [ADDRESS_892868]  the infusion bags from 
light (still direct sun light should be avoided) while study drug is being administered to the patient. At the site’s discretion, the crizanlizumab saline bag may be administered via gravity feed,  a syringe-type pump, or an infusion pump. Following completion  of the study drug 

[COMPANY_001]  
Amended Protocol Versio n [ADDRESS_892869] another 25 mL 0.9% sodium chloride should be administered  in order to clear 
the infusion line of drug and ensure all study drug has been administered to the patient. The 
patient should be monitored for one (1) hour following infusion. For more details please refer to the [Pharmacist Manual].  
 
6.6.1  Study treatment packaging and la beling  
Study treatment, crizanlizumab, will be provided as global clinical open supply and will be 
packed and labeled under the responsibility of [COMPANY_001], Drug Supply Management. 
Study treatment  labels  will comply with the legal  requirements  of each country and will include 
storage conditions, a unique medication  number (corresponding to study treatment and strength) 
or randomization number if appropriate.  
 
Table 6-4 Packaging and labeling  
Study  treatments  Packaging  Labeling (and dosing frequenc y) 
SEG101  Vials containing 10 mL at a 
concentration of 10 mg/mL  Labeled as ‘SEG101’ (at Week1 Day1, 
Week3 Day 1, Week 7 Day 1 and at 
Day 1 of every 4- weeks)  
 
 
6.6.[ADDRESS_892870] be received  by [CONTACT_661895], handled and stored 
safely and properly (protected from light, refer to the pharmacy manual and labels for more 
detail), and kept in a secured location to which only the investigator and designated site personnel have access.  Upon receipt, the study treatment should be stored according to the 
instructions specified in the [Pharmacy Manual] and in the [Investigator’s Brochure].  
 
Table 6-5 Supply and storage of study treatments  
Study  treatments  Supply  Storage  
 
SEG101  Centrally supplied  by [CONTACT_661896]  
 
 
6.6.3  Study drug compliance and accountability  
 
[IP_ADDRESS]  Study drug compliance  
Compliance will be assessed by [CONTACT_661897]/her designee and will be verified by [CONTACT_661898]. This information must be captured in the source document and in the Drug Accountability Form. 
 
[IP_ADDRESS]  Study drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Drug accountability will be noted by [CONTACT_121191]. 
At study close -out, and, as appropriate during the course of the study, the investigator  will return 
all used and unused study treatment, packaging, drug labels, and a copy of the completed drug 

[COMPANY_001]  
Amended Protocol Versio n 01 Clean  Confidential  Page 51
5 Protocol No. 
  
 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address  provided in the investigator 
folder at each  site. 
 
[IP_ADDRESS]  Handling of other study  treatment  
Not applicable.  
 
6.6.[ADDRESS_892871] party, as appropriate 
 
7 Visit schedule and  assessments  
7.1 Study flow and visit schedule  
Table 7 -1 lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source documentation. 
No CRF will be used as a source document. The table  indicates  which  assessments produce data to  be entered  into the clinical  database (D) 
or remain in source documents only (S) (“Category” column). 
Allowed visit windows are specified as follows: 
• Screening assessments, apart from those listed below, must occur within 35 days prior to 
the enrolment as per Table 7-1. 
• No visit window is allowed Week 1 Day 1 to Week 2 Day 1. And from Week 15 Day 1 to Week 16 Day 1 (or following the first week of steady state as specified in Table 7-5).  
• A ±1 days visit window is permitted on assessments Week 3 Day 1, Week 17 Day 1 and Week 18 Day  1 
• For all other visits a general ±3 days visit window is permitted on assessments to take into account scheduling over public holidays. 
• A + [ADDRESS_892872]-treatment phase (last infusion + 105 days) is allowed 
Every effort should be made to follow the schedule outlined in Table 7-1. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 52
2 Protocol No. 
  
 
 
Table 7-1 Visit evaluation schedule  
 
 
Category  Protocol 
Section Screening phase  Treatment phase  End of treatmen t (EoT)  Follow up phase  
                    
    
Wk1 
Wk1 D2  
Wk1 D4  
Wk2 
Wk3 
Wk7 
WK11  
Wk15  
Wk15 D2  
Wk15 D4  
Wk16  
Wk17  
Wk18  Wk   
Visit on Day1 of the week (unless 
otherwise specified)
a  
 
D-[ADDRESS_892873] 
infusio 
n + 
 D-1 4qWk  infusion  105d  
Screening  
Obtain Study Informed 
Consent  D 7.1.2  X                 
Disposition assessment  
Study disposition  D 7 X               X X 
Patient history  
Demography  D [IP_ADDRESS]  X                 
Inclusion/exclusion 
criteria  D [IP_ADDRESS]  X                 
Medical History  D [IP_ADDRESS]  X                 
ECOG performance 
status  D [IP_ADDRESS]  X                 
Sickle Cell – Vaso - 
Occlusive Crisis history  D [IP_ADDRESS]  X                 
Alcohol history  D [IP_ADDRESS]  X                 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 53
2 Protocol No. 
  
 
 
Category  Protocol 
Section Screening phase  Treatment phase  End of treatmen 
t (EoT)  Follow 
up 
phase  
                    
    
Wk1 
Wk1 D2  
Wk1 D4  
Wk2 
Wk3 
Wk7 
WK11  
Wk15  
Wk15 D2  
Wk15 D4  
Wk16  
Wk17  
Wk18  Wk   
Visit on Day1 of the 
week (unless 
otherwise specified)a  
 
D-[ADDRESS_892874] 
infusio 
n + 
 D-1 4qWk  infusion  105d  
Smoking history  D [IP_ADDRESS]  X                 
Drug Screen (drug, alcohol)
d S 
/ 
D [IP_ADDRESS]  X                 
Physical examination  
Physical examination  S [IP_ADDRESS]  X               X  
Abbreviated physical 
exam  S [IP_ADDRESS]   X    X X X X      X   
Vital signs  D [IP_ADDRESS]  X X X X X X X X X X X X X X X X  
Height  D [IP_ADDRESS]  X                 
Weight  D [IP_ADDRESS]  X X    X X X X      X   
Laboratory 
assessments   [IP_ADDRESS]                   
Hematology  D [IP_ADDRESS].1  Xb X X X X X X X X X X X X X X X X 
Chemistry  D [IP_ADDRESS].2  Xb X X X X X X X X X X X X X X X X 
Coagulation  D [IP_ADDRESS].4  Xb X X X X X X X X X X X X X X X X 
Urinalysis  
(microscopic or 
macroscopic)  D [IP_ADDRESS].3  Xb X X X X X X X X X X X X X X X X 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 54
2 Protocol No. 
  
 
 
Category  Protocol 
Section Screening phase  Treatment phase  End of treatmen 
t (EoT)  Follow 
up 
phase  
                    
    
Wk1 
Wk1 D2  
Wk1 D4  
Wk2 
Wk3 
Wk7 
WK11  
Wk15  
Wk15 D2  
Wk15 D4  
Wk16  
Wk17  
Wk18  Wk   
Visit on Day1 of the 
week (unless 
otherwise specified)a  
 
D-[ADDRESS_892875] 
infusio 
n + 
 D-[ADDRESS_892876]  S [IP_ADDRESS].[ADDRESS_892877]  S [IP_ADDRESS].5   X    X X X X      X   
Hepatitis testing  D [IP_ADDRESS].[ADDRESS_892878]  D [IP_ADDRESS].7  X                 
Efficacy assessments   7.2.1                   
Sickle Cell – Vaso - 
Occlusive Crisis Event  D 7.2.[ADDRESS_892879] x -ray D 7.2.1  Xe                 
Hospi[INVESTIGATOR_059]  D 7.2.1   Continuous   
Prior/concomitant 
medications – Analgesic  D 6.4 X Continuous   
Prior/concomitant 
medications – 
Hydroxyurea  D 6.4 X Continuous   
Transfusion  D 7.2.1  X Continuous   
Employment status and 
sick time  D 7.2.1  X X    X X X X      X X  
Safety assessments  
ECG  D [IP_ADDRESS].1  X X X X X X X X X X X X X X Xc X X 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 55
2 Protocol No. 
  
 
 
Category  Protocol 
Section Screening phase  Treatment phase  End of treatmen 
t (EoT)  Follow 
up 
phase  
                    
    
Wk1 
Wk1 D2  
Wk1 D4  
Wk2 
Wk3 
Wk7 
WK11  
Wk15  
Wk15 D2  
Wk15 D4  
Wk16  
Wk17  
Wk18  Wk   
Visit on Day1 of the 
week (unless 
otherwise specified)a  
 
D-[ADDRESS_892880] 
infusio 
n + 
 D-1 4qWk  infusion  105d  
Adverse Event/ Serious 
Adverse Event  D 8 X Continuous  
Prior/concomitant 
medications  D 6.4 X Continuous  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 56
2 Protocol No. 
  
 
 
Category  Protocol 
Section Screening phase  Treatment phase  End of treatmen 
t (EoT)  Follow 
up 
phase  
                    
 
Visit on Day1 of the 
week (unless 
otherwise specified)a    
 
 
D-[ADDRESS_892881] 
infusio 
n + 
105d  
Pharmacokinetics  
PK samplingg D 7.2.[ADDRESS_892882] been done more than 14 days before Week 1 Day 1.c From 
week 51 will be done every 24 weeks (Wk 75, 99, 123, 147 and 171 (See Table 7- 4 and Table 7-5 )) 
d Drug results will be captured in database. Blood alcohol screen result will be captured in source  
 
  
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 57
7 Protocol No. 
  
 
 
7.1.1  Molecular  pre-screening  
Not applicable.  
 
7.1.2  Screening 
After signing the study ICF, the screening assessments will be done within 1 to 35 days prior 
to Week 1 Day 1 (see Table [ADDRESS_892883] of assessments to be performed). The investigator will 
obtain consent / assent of patients and/or parents according to local procedures. 
Re-screening of patients is only allowed once per patient if the patient was not enrolled in the 
treatment phase before. In this case a new Subject Number will be assigned to the patient and 
the patient will be identified with this new number for the rest of his/her participation in the study. If patient has been enrolled and treated, re-screening of patient is not allowed. 
In case rescreening  occurs,  all evaluations re-assessed  should meet  the eligibility  criteria.  A new 
informed  consent form  must be signed only if there is  an interruption  in the patient’s  eligibility 
evaluation and the investigator chooses to re -screen the patient following screen failure. If a 
new informed consent form is signed, AEs and medical history will be assessed relative to the 
new informed consent date. 
For laboratory evaluations used to determine eligibility, a repeated evaluation within the 
screening window is permitted for screening results out of the defined range before screen failing  the patient.  If the repeated  laboratory result  meets  the criteria,  that result may be used to 
determine  eligibility.  If the repeated  laboratory result  does not meet  the criteria,  the patient  will 
be considered a screening failure. For details of assessments, see Table 7-1 . 
 
 
 
[IP_ADDRESS]  Eligibility  screening  
The investigator is responsible to ensure only subjects who meet all inclusion and do not meet any exclusion criteria are included in the study. 
Patient  eligibility  will be checked  by [CONTACT_661899]. 
The eligibility  check form will be sent from the site to the Sponsor via email for evaluation. 
Upon confirmation of eligibility, the Sponsor will assign the patient either to the 5.0 mg/kg or 
7.5 mg/kg treatment  group (according  to the enrolment chronological order)  and will return  the 
signed eligibility check form via email to the site. The investigator site will then be allowed to assign treatment to the patient. Please refer and comply with detailed guidelines in the Eligibility check user  guidelines. 
 
[IP_ADDRESS]  Information to be collected on screening  failures  
Patients  who sign an informed  consent but fail to be enrolled  (patient  who does not enter  in the 
treatment phase) for any reason will be considered a screen failure. The reason for not being started  on treatment  will be entered  on the Screening  Phase Disposition  Page.  The demographic 
information, informed consent, Inclusion/Exclusion pages and, if  applicable, withdrawal of 
informed  consent must also be completed  for Screen  Failure  patients.  No other data will be 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 58
7 Protocol No. 
  
 
entered into the clinical database for patients who are screen failures, unless the patient 
experienced an SAE during the Screening Phase (see Section 8 for SAE reporting details). 
If a screen  failure  patient  experiences  an AE which  does not meet  the SAE  criteria,  details  about 
the AE will be recorded only in the investigator’s source documents. In case of an SAE after 
signing of main  study informed  consent, data must be recorded  on both the AE and SAE  forms.  
If the patient fails to be enrolled, the Sponsor must be notified within 2 days of the screen fail via email that the patient was not enrolled.  
 
[IP_ADDRESS]  Patient demographics and other baseline  characteristics  
Subject demographic characteristics, which include age,  gender, self -identified race and 
ethnicity, will be collected.  
Background medical information, including Sickle Cell and Vaso – Occlusive Crisis History, 
ECG, relevant and current medical history and alcohol and smoking history will also be collected.  
Othe r baseline characteristics  and assessments  performed  at screening  for eligibility  are detailed 
in Table 7-1. 
 
7.1.[ADDRESS_892884] 45 patients will receive crizanlizumab at 5mg/kg on week 1 day 1, week 3 day 1 and then every 4 weeks (week 7 day 1, week 11 day 1, etc.). Once [ADDRESS_892885] evaluable PK and PD data (or a total of up to 45 patients are enrolled) at the 5.0 mg/kg dose, 10 additional patients  will receive crizanlizumab  at 7.5 mg/kg on week  1 day  1, week  3 day 1 and  then every 
4 weeks.  
All patients will continue to receive study treatment and be followed as per the schedule of assessments,  as long as patients  derive benefit  from  crizanlizumab  until any combination of the 
following will apply to all patients: 
• All patients have died or discontinued from the study 
• Crizanlizumab is commercially available for this patient population, and patients are eligible to be prescribed the commercial  drug 
• Another clinical study becomes available that can continue to provide crizanlizumab in this patient population and all patients ongoing are eligible to be transferred to that clinical study. 
Full PK and PD profiles will be collected on week 1 days 1, 2 and 4, on day 1 of weeks 2, 3, 7 
and 11. From week 15 day 1, additional full PK and PD profiles will be collected on days 1, 2, and 4 of week  15 (or at the time  of the fifth infusion),  on day 1 of weeks  16, 17, 18 and 
19. 
However,  if the dose was interrupted  and/or an infusion  was delayed  before  week  15, then 
after  [ADDRESS_892886] been  given without  an interruption  of >[ADDRESS_892887] infusion).  
Pre-dose PK and PD sampling will be collected prior to each infusion until week 51.  
 
 
For details of assessments, see Table 7 -1 and Table 7 -5. 
 
7.1.5 Discontinuation of study  treatment  
Patients may voluntarily discontinue from the study treatment for any reason at any time. If a 
patient decides to discontinue from the study treatment, the investigator should make a 
reasonable effort (e.g. telephone, e -mail, letter) to  understand  the  p rimary reason  for 
this decision and record this information in the patient’s chart and on the appropriate CRF pages. They may be considered withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to follow-up for any other reason. 
The investigator may discontinue study treatment for a given patient if he/she believes that 
continuation would be detrimental to the patient’s well-being. 
In addition to the mandatory reasons  for discontinuation of study treatment  listed  in Section  6.3, 
study treatment must also be discontinued under the following circumstances:  
• Pregnancy  
• Lactation  
• Death  
• Subject/Guardian  decision 
• Adjustments to study treatment due to toxicity that result in treatment discontinuation (see  
Section  6.3) 
• Use of prohibited medication (see Section  6.4).  
• Any other protocol deviation that results  in a significant risk to the patient’s  safety.  
Patients who discontinue study treatment should NOT be considered withdrawn from the 
study. They should return for the assessments indicated in Section 7.2.1 for an EOT visit and a safety Follow -Up visit. If they fail to retu rn for these assessments for unknown reasons, every 
effort (e.g. telephone, email, letter) should be made to contact [CONTACT_15026]  
7.1.6. 
Patients who discontinue study treatment should undergo an End of Treatment (EOT) visit 
followed by a 105 day safety follow -up. At EOT visit, all the assessments as listed in Table 7 - 
1 will be performed. If the decision to discontinue  the patient occurs at a regularly scheduled 
visit,  that visit may serve as the EOT  visit rather  than having the patient  return  for an additional 
visit.  
 
[IP_ADDRESS]  Replacement policy  
Not Applicable 

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892888]: 
• Does not want to participate in the study anymore, and 
• Does not allow further collection of personal data 
In this situation,  the investigator should make a reasonable effort  (e.g. telephone,  e-mail,  letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_109032]-up. 
All efforts should be made to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as detailed in the assessment table.  
[COMPANY_001]/sponsor will continue to keep  and use collected  study information  (including any data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to applicable law. 
All biological samples not yet analyzed at the time of withdrawal may still be used for further testing/analysis  in accordance with the terms  of this protocol and of the informed  consent form.  
 
7.1.[ADDRESS_892889] safety evaluations for 5 half-lives (105 days) after the last dose of study treatment. Once an AE is detected, investigators are required to follow this AE until its resolution or stabilization. Refer to Section 8.1.[ADDRESS_892890] the patient should be documented in the source documents (e.g., dates  of telephone calls,  registered  letters, 
etc.).  
 
7.1.[ADDRESS_892891] to  follow -up 
For patients whose status is unclear because they fail to appear for study visits without stating an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_661900] [ADDRESS_892892] to follow up should be recorded as such on the appropriate 
CRF.  
 
7.2 Assessment types  
7.2.1  Efficacy  assessments 
VOC  is defined as  pain crises  (defined  as an acute  onset of pain  for which  in the opi[INVESTIGATOR_661856]- occlusion and 
which requires therapy with oral or parenteral opi[INVESTIGATOR_49342]) as well as other complicated crises, such as acute chest syndrome (ACS), priapi[INVESTIGATOR_8801] , and hepatic or splenic 
sequestration. 
For purposes of this study, the following detailed definitions will be used to identify each sub- 
type of VOC event: 
1. Uncomplicated pain crisis is defined as an acute epi[INVESTIGATOR_661857] a vaso-occlusive event; and requiring treatment with a parenteral or oral opi[INVESTIGATOR_49342]; but is NOT classified as an acute chest syndrom e, hepatic 
sequestration, splenic sequestration or priapi[INVESTIGATOR_8801]. The end of an uncomplicated pain crisis will be considered the resolution of acute pain, such that residual pain (or absence of any pain) is considered to be chronic, and the current pain medication regimen is considered to be for this chronic pain.  
2. Acute Chest Syndrome (ACS) is defined on the basis of the finding of a new pulmonary infiltrate involving at least one complete lung segment that was consistent with alveolar consolidation, but excludi ng atelectasis (as indicated by [CONTACT_13190] X -ray). At least one of the 
following additional signs or symptoms needs to be present as well: chest pain, a temperature of more than 38.5°C, tachypnea, wheezing or cough. ACS will be considered resolved when the patient is no longer hospi[INVESTIGATOR_057] (unless for reason other than the ACS epi[INVESTIGATOR_1865]) and none of the additional signs or symptoms above are present.  
3. Priapi[INVESTIGATOR_661858] [ADDRESS_892893] 2  hours. 
4. Hepatic sequestration is defined on the basis of findings of right upper quadrant pain, an enlarged liver, and an acute decrease in hemoglobin concentration (e.g. a decrease in hemoglobin of ~ 2 g/dL). Acute hepatic sequestration will be considered resolved when right upper quadrant pain has returned to baseline (pre-event) levels and hemoglobin has been stable for 24  hrs. 
5. Splenic sequestration if defined on the basis of findings of left upper quadrant pain, an enlarged spleen, and an acute decrease in hemoglobin concentration (e.g., a decrease in hemoglobin of ~ 2 g/dL). Acute splenic sequestration  will be considered  resolved  when 
left upper quadrant pain has returned to baseline (pre-event) levels and hemoglobin has been stable for 24  hrs. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 62
7 Protocol No. 
  
 
Associated  conditions in SCD  (e.g., intermittent or chronic pain due to ankle/leg  ulcers,  aseptic 
necrosis of bone or gout) should not be considered VOC event. Similarly, complications such 
as pulmonary, cardiac,  or renal  failure  are not themselves  to be considered  crises.  If such events 
precipi[INVESTIGATOR_661859], the VOC event will be documented  separately.  
For each visit to a medical facility for a pain epi[INVESTIGATOR_661860] a VOC, the following information must be documented in the eCRF: diagnostic evaluation for the epi[INVESTIGATOR_1865], patient treatment and management, course, duration of the crisis, and outcome. For  patients who are 
treated at medical facilities other than the study site, summary documents (e.g. ER or hospi[INVESTIGATOR_8838]) will need to be obtained. Patients will be issued an investigational study participation card that requests this information and can be presented at each medical facility visit.  
Patients  should be encouraged  to contact  [CONTACT_737] (or surrogate  from  the site) when  they 
believe they are experiencing a VOC that they believe they can manage at home, both for treatment guid ance and for accurate information may be obtained for the VOC eCRF page. 
VOCs  treated  at home but not documented by a telephone call within  24 hours of onset will not 
be counted as a VOC, due to concern over the accuracy of patient recall of all relevant  details.  
If a patient experiences a VOC surrounding a protocol -scheduled visit day, and the patient 
presents for this visit, it will be counted as a VOC that led to a healthcare visit (provided the event meets the criteria for VOC discussed above). VOC is not a known contra -indication, but 
dosing during a crisis should be at investigator’s discretion. 
Any VOC symptoms occurring within [ADDRESS_892894] 
be repeated in case of suspected  ACS.  
Transfusion data should be collected  from  30 days prior to Screening  until the patient  EOT  visit. 
Patients participating in a chronic transfusion program (pre -planned series of transfusions for 
prophylactic purposes) are not eligible.  Epi[INVESTIGATOR_661861].  
 
Table 7-2 Vaso- Occlusion Crisis Assessment Collection  Plan  
 
Procedure / Assessment 
collection plan  Screening/Baseline  During Treatment/Follow -up 
Chest X -Ray Mandated  If clinically indicated  
Vaso -Occlusion Crisis 
information  Mandated  Mandated, when VOC crisis 
occurs  
Concomitant medication – 
Analgesic  If clinically indicated  Mandated, when VOC crisis 
occurs  
Hospi[INVESTIGATOR_661862], when VOC crisis 
occurs and hospi[INVESTIGATOR_661863] 01 Clean  Confidential  Page 63
7 Protocol No. 
  
 
Procedure / Assessment 
collection plan  Screening/Baseline  During Treatment/Follow -up 
Employment status and sick 
time If clinically indicated  If clinically indicated  
 
7.2.2 Safety and tolerability  assessments  
Safety will be monitored by [CONTACT_15033], vital signs, ECG, laboratory 
assessments including hematology, chemistry, coagulation, urinalysis and as well as collecting of the adverse events at every visit. For details on AE collection and reporting, refer to Section  
8. 
 
[IP_ADDRESS]  Physical  examination  
The physical examination must be performed by [CONTACT_661901] 7 -1. 
A complete physical examination will include the examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities,  vascular  and neurological. If indicated  based  on medical  history and/or symptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed. A complete physical examination will be performed at Screening and within [ADDRESS_892895] infusion. 
An abbreviated (short) physical exam will include the examination of general appearance and 
vital signs (blood pressure [BP] and pulse), as well as additional components of the physical exam , as needed  based  on observed signs or reported  symptoms. A short physical exam  will be 
performed at all visits for which there is a scheduled study drug infusion. 
Significant findings that were  present  prior to the signing of informed  consent must be included 
in the Medical  History  page on the patient’s  CRF.  Significant new findings that begin or worsen 
after informed consent must be recorded on the Adverse Event page of the patient’s CRF.  
 
[IP_ADDRESS]  Vital  signs  
Vital signs include blood pressure (supi[INVESTIGATOR_30752]), pulse 
measurement, respi[INVESTIGATOR_661864] 7 - 
1. 
 
[IP_ADDRESS]  Height and  weight  
Height will be measured at screening.  
Body weight (in indoor clothing, but without shoes) will be measured at screening and at all visits  for which  there is a scheduled  study drug infusion (for dosing), as specified  in Table 7-1. 
 
[IP_ADDRESS]  Performance status  
ECOG performance status scale will be assessed at screening.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 64
7 Protocol No. 
  
 
[IP_ADDRESS]  Laboratory  evaluations  
Clinical laboratory analyses  (hematology, chemistry,  urinalysis, coagulation, hepatitis  and HIV 
markers and drug screen) are to be performed centrally unless otherwise noted in Table 7 -3 
according to the schedule of assessments and collection plan outlined in Table 7 -1. Details on 
the collection, shipment of samples and reporting of results by [CONTACT_661902]/Flowchart. Visit windows are 
allowed for all visits (except from Week 1 Day to Week 2 Day 1 and Week 15 Day 1 to Week 16 Day 1 (or following the first week of steady state) see Section  7.1).  
[COMPANY_001] must be provided with a copy of the central laboratory’s certification (if applicable), and a tabulation of the normal ranges and units  of each parameter collected in the eCRF. Any 
changes  regarding  normal ranges  and units for laboratory  values  assessed  during the study must 
be reported via an updated tabulation indicating the new effective date. Additionally, if at any time a patient  has laboratory parameters  obtained from  a different  (outside) laboratory, [COMPANY_001] 
must be provided with a copy of the certification  and a tabulation  of the normal ranges  and units 
for this laboratory as well. The investigator is responsible for reviewing all laboratory reports for patients in the study and evaluating any abnormalities for clinical significance.  
For assessment of patients’ eligibility for the study, only laboratory results from the central  laboratory will be used  (except  in case of re-sampling  at Day -[ADDRESS_892896] be provided). 
Unscheduled local laboratory assessments may be performed  if medically indicated to 
document a (potential)  AE, if central  laboratory  results  are unevaluable or inconclusive, or when 
the treating physician cannot wait for central laboratory results for decision making. In this 
particular situation, if possible, the blood sample obtained at the same time point should be submitted to the central laboratory for analysis in parallel with local analysis.  
The results  of the local  laboratory will be recorded  in the eCRF  if any the following  criteria  are 
met: 
• A treatment decision was made based on the local results,  or 
• There are no concomitant central results available, or  
• Local lab results document an AE not reported by [CONTACT_6626], or 
• Local lab results document an AE where the severity is worse than the one reported by [CONTACT_6626],  or 
• Eligibility had to be based on the local lab results due to pending / missing central lab results.  
At any time during the study up to safety  follow-up, abnormal laboratory parameters  which  are 
clinically relevant and requ ire an action to be taken with study treatment (e.g., require dose 
modification and/or interruption of study treatment, lead to clinical symptoms or signs, or require therapeutic intervention), whether specifically requested in the protocol or not, will be  
recorded  on the AE eCRF  page.  The severity  of laboratory data will be graded  using the 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 65
7 Protocol No. 
  
 
Common Terminology Criteria  for Adverse events  (CTCAE)  version 4.03. Additional analyses 
are left to the discretion of the investigator.  
 
Table 7-[ADDRESS_892897] Name  
[CONTACT_661914]: Hematocrit, Hemoglobin, MCH, MCHC, MCV, Hemoglobin 
electrophoresis or HPLC, Reticulocytes (%), Platelets, Red blood cells, White 
blood cells, RBC Morphology, Differential (Basophils, Eosinophils, 
Lymphocytes, Monocytes, Neutrophils, Bands, Other (absolute value 
preferred, %s are acceptable))  
Chemistry  Central: Albumin, Alkaline phosphatase, ALT, AST, Lactate dehydrogenase 
(LDH), Bicarbonate, Calcium, Magnesium, Phosphorus, Chloride, Sodium, 
Potassium, Creatinine, Creatine kinase, Direct Bilirubin, Indirect Bilirubin, Total 
Bilirubin, Total Cholesterol, LDL, HDL, Total Protein, Triglycerides, Blood Urea 
Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose (fasting), Creatinine Clearance (eGFR),  
Local: Blood alcohol screen  
Urinalysis  Local: Macroscopic Panel (Dipstick) will be done locally (Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes esterase, Nitrite, pH, Protein, Specific Gravity, 
Urobilinogen)  
Central: Microscopic Panel (Red Blood Cells, White Blood Cells, Casts, 
Crystals,  Bacteria, Epi[INVESTIGATOR_1663]) performed, if a positive dipstick.  
Central: Urine Drug Screen (Amphetamine, Barbiturate, Benzodiazepi[INVESTIGATOR_050], Cannabinoids, Cocaine, Methadone, Phencyclidine, Opi[INVESTIGATOR_2573], Tricyclics, Methamphetamine)  
 
Coagulation  Central: Prothrombin time (PT), International normalized ratio [INR], Partial 
thromboplastin time (PTT) or Activated partial thromboplastin time (APTT)  
Hepatitis markers  Central: HBV -DNA, HBsAg, HBsAb, HBcAb, HCV RNA -PCR, HCV Ab (at  
Screening only)  
Additional tests  Central: HIV Ab (at Screening only)  
Pregnancy Test  Central: Serum pregnancy test (at Screening, EoT and end of safety follow -up 
only),  
Local: urine pregnancy test (before each infusion).  
 
[IP_ADDRESS].1  Hematology  
Hematology tests are to be performed centrally according to the schedule of assessments and 
collection plan outlined in Table 7 -1. Detailed hematology panel is described on Table 7 -3. 
 
[IP_ADDRESS].2  Chemistry  
Chemistry tests are to be performed centrally (except blood alcohol screen test) according to 
the schedule of assessments and collection  plan outlined in Table 7-1. Detailed  chemistry  panel 
is described on Table 7-3 . 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 66
7 Protocol No. 
  
 
Glomerular filtration rate (using CKD -EPI [INVESTIGATOR_14420]) will be done centrally: 
 
[IP_ADDRESS].3  Urinalysis  
Macroscopic  urinalysis dipstick  analysis  (WBC,  blood, protein and  glucose) will be performed 
locally according to the schedule of assessments and collection plan outlined in Table 7 -1. 
Detailed urinalysis panel is described on Table 7- 3. 
Microscopic analysis will be performed centrally only in case of positive dipstick. 
 
 
 
 
 
 
[IP_ADDRESS].[ADDRESS_892898]  is suspected 
to be pregnant (urine or serum).  
Each pregnancy in a subject on study drug must be reported to the sponsor within 24 hours of learning of its occurrence. See Section 8.4 for detailed reporting and follow up procedures. 
 
[IP_ADDRESS].6  Hepatitis markers  
Hepatitis testing will be performed centrally as per Table 7 -1. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 67
7 Protocol No. 
  
 
[IP_ADDRESS].[ADDRESS_892899]  
HIV and Drug screen will be performed centrally as per Table 7 -1. 
 
[IP_ADDRESS]  Cardiac assessments  
 
[IP_ADDRESS].1 Electrocardiogram  (ECG)  
Standard 12- lead ECGs will be performed (in the supi[INVESTIGATOR_2547]) after the patient has been 
resting  for 5-10 min prior to each time point indicated  in Table  7-4. ECG  assessments  are to be 
done prior to blood collection sampling. 
When triplicate ECG are required, the individual ECGs should be recorded approximately 2 
minutes apart.  
The QTcF values using Fridericia’s correction (formula is provided below) should be used. 
The mean  QTcF  value will be calculated  from  the triplicate  ECGs  for each patient.  Unscheduled 
triplicate ECGs will be performed also in case QTcF ≥500 ms has been observed. 
 
Table 7-4 Central ECG collection plan 
 
Period  Week / Day  Time a ECG Type  
Screening  Day -[ADDRESS_892900] -dose (± 5 min end of 
infusion)  Triplicate [ADDRESS_892901] -dose (± 5 min)  Triplicate [ADDRESS_892902] -dose (± 30 min)  Triplicate [ADDRESS_892903] -dose (± 30 min)  Triplicate [ADDRESS_892904] -dose (± 30 min)  Triplicate [ADDRESS_892905] -dose (± 2 hr)  Triplicate [ADDRESS_892906] -dose (± 2 hr)  Triplicate [ADDRESS_892907] -dose (± 24 hr)  Triplicate [ADDRESS_892908] -dose (± 5 min end of 
infusion)  Triplicate [ADDRESS_892909] -dose (± 5 min)  Triplicate [ADDRESS_892910] -dose (± 30 min)  Triplicate [ADDRESS_892911] -dose (± 30 min)  Triplicate [ADDRESS_892912] -dose (± 30 min)  Triplicate [ADDRESS_892913] -dose (± 2 hr)  Triplicate [ADDRESS_892914] -dose (± 2 hr)  Triplicate 12 Lead  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 68
7 Protocol No. 
  
 
Period  Week / Day  Time a ECG Type  
 Week [ADDRESS_892915] -dose (± 24 hr)  Triplicate [ADDRESS_892916] -dose (± 24 hr)  Triplicate [ADDRESS_892917] -dose (± 24 hr)  Triplicate 12 Lead  
Week 19 Day 1  Pre-dose b Triplicate 12 Lead  
Week 23 Day 1  Pre-dose b 12 Lead  
Week 27 Day 1  Pre-dose b 12 Lead  
Week 31 Day 1  Pre-dose b 12 Lead  
Week 35 Day 1  Pre-dose b 12 Lead  
Week 39 Day 1  Pre-dose b 12 Lead  
Week 43 Day 1  Pre-dose b 12 Lead  
Week 47 Day 1  Pre-dose b 12 Lead  
Week 51 Day 1  Pre-dose b 12 Lead  
Week 75 Day 1  Pre-dose b 12 Lead  
Week 99 Day 1  Pre-dose b 12 Lead  
Week 123 Day 1  Pre-dose b 12 Lead  
Week 147 Day 1  Pre-dose b 12 Lead  
Week 171 Day 1  Pre-dose b 12 Lead  
End of Treatment  EoT Anytime  12 Lead (triplicate 
12 lead if EoT 
before wk 15)  
Follow -up Last dosing + [ADDRESS_892918] be performed at the same timepoint as the PK timepoint. In case the PK 
timepoints are amended, the same amendment should apply to the ECG assessments.  
b within 24hr before dose administration  
Note: In order to ensure ECG evaluation is received from the central laboratory for eligibility 
assessment, it is advisable to perform the ECG at least 72 hours prior to the scheduled 
enrollment date.  
In the event  that a QTcF  value of > [ADDRESS_892919] study drug intake to determine  the drug exposure (refer  to Section  7.2.3).  In 
case of QT prolongation, study drug should be discontinued until normalized as described in Section  [IP_ADDRESS] 
Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at any time during the study as clinically  indicated.  Unscheduled ECGs  with clinically  significant 
findings should be collected in triplicate. Local cardiologist ECG  assessment may also be 
performed at any time during the study at the discretion of the investigator. 
All ECGs collected during the study, including unscheduled safety triplicate ECGs with 
clinically  relevant  findings, should be transmitted  to the central  core ECG  laboratory for review. 
The results of the centrally assessed ECGs are automatically transferred into the clinical  

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892920] be made by a qualified physician and documented on the ECG CRF page. Each ECG  tracing  should be labeled  with the study number, patient  initials  (where  regulations permit), 
subject number, date, and kept in the source documents at the study site. 
Clinically  significant ECG  abnormalities  present  at screening  should be reported  on the Medical 
History CRF page. New or worsened clinically significant findings occurring after informed consent must be recorded on the Adverse Events CRF page.  
Timing of study procedures: 
 
 
 
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 70
7 Protocol No. 
  
 
7.2.3  Pharmacokinetics,  pharmacodynamics, and  immunogenicity  
Serial blood samples will be collected from all patients to assess PK and PD of crizanlizumab. 
Non-compartmental PK and PD parameters will be derived from each individual serum 
concentration - or inhibition- time profile  using appropriate methods and software. Refer to 
Section 10.5.4 for a table of PK parameters that will be derived.  
 
 
 
[IP_ADDRESS]  Pharmacokinetic, pharmacodynamic, and immunogenicity blood collection and handling 
At specified time points described in Table [ADDRESS_892921] venipuncture or an indwelling cannula inserted in a forearm vein. 4.5 mL blood draws should be collected when PK and PD are specified. 8 mL blood draws should be collected when PK, PD and inmunogenicity (IG) samples are needed. 
The blood samples will be allowed to clot for approximately 30 minutes at room temperature 
and then centrifuged for 10 minutes at approximately 3000g. Each serum sample will be 
aliquoted, and transferred into freezer -proof polypropylene screw -cap tubes ([ADDRESS_892922] 0.5 mL serum in each tube). The serum  tubes will be frozen  within  90 minutes  of venipuncture and kept below - 70°C 
in an upright position pending shipment and analysis.  
Each serum samples should be labeled with the appropriate study, center and subject numbers, as well as the sequential PK/PD/IG sample and PK/PD/IG collection number with a unique sample number. The actual collection date and time of each sample will be en tered on the 
PK/PD/IG Blood Collection eCRF pages. 
Refer to the [CSEG101A2202 Laboratory Manual] for detailed instructions for the collection, 
handling, and shipment of samples.  
 
Table 7-5 Pharmacokinetic, pharmacodynamics and immunogenicity blood 
collection log 
 
Week  Day Scheduled timepoint 
following the 
initiation of infusion  PK collection 
number/Dose 
reference ID  PK 
sample 
No PD 
sample 
No IG 
sample 
No Sample 
volume 
(mL)  
1 1 Pre-dose  1 -- 1 101 201 8 
1 1 0.5h (± 5 min end of 
infusion)  1 -- 2 -- -- 2.5 
1 1 1h (± 5 min)  1 -- 3 -- -- 2.5 
1 1 2h (± 30 min)  1 -- 4 102 -- 4.5 
1 1 4h (± 30 min)  1 -- 5 -- -- 2.5 
1 1 6h (± 30 min)  1 -- 6 -- -- 2.5 
1 2 24h (± 2 hr)  1 -- 7 103 -- 4.5 
1 4 72h (± 2 hr)  1 -- 8 104 -- 4.5 
2 1 8 days (± 24 hr)  1 -- 9 105 -- 4.5 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 71
7 Protocol No. 
  
 
Week  Day Scheduled timepoint 
following the 
initiation of infusion  PK collection 
number/Dose 
reference ID  PK 
sample 
No PD 
sample 
No IG 
sample 
No Sample 
volume 
(mL)  
3 1 Pre-dose (± 24 hrc) 2 101a 10 106 202 8 
7 1 Pre-dose (± 24 hrc) 3 201a 11 107 203 8 
11 1 Pre-dose (± 24 hrc) 4 301a 12 108 204 8 
15b 1 Pre-dose (± 24 hrc) 5 401a 13 109 205 8 
15b 1 0.5h (± 5 min end of  5 -- 14 -- -- 2.5 
  infusion)        
15b 1 1h (± 5 min)  5 -- 15 -- -- 2.5 
15b 1 2h (± 30 min)  5 -- 16 110 -- 4.5 
15b 1 4h (± 30 min)  5 -- 17 -- -- 2.5 
15b 1 6h (± 30 min)  5 -- 18 -- -- 2.5 
15b 2 24h (± 2 hr)  5 -- 19 111 -- 4.5 
15b 4 72h (± 2 hr)  5 -- 20 112 -- 4.5 
16b 1 8 days (± 24 hr)  5 -- 21 113 -- 4.5 
17b 1 15 days (± 24 hr)  5 -- 22 114 -- 4.5 
18b 1 22 days (± 24 hr)  5 -- 23 115 -- 4.5 
19b 1 Pre-dose c 6 501a 24 116 206 8 
23 1 Pre-dose c 7 601a 25 117 207 8 
27 1 Pre-dose c 8 701a 26 118 208 8 
31 1 Pre-dose c 9 801a 27 119 209 8 
35 1 Pre-dose c 10 901a 28 120 210 8 
39 1 Pre-dose c 11 1001a 29 121 211 8 
43 1 Pre-dose c 12 1101a 30 122 212 8 
47 1 Pre-dose c 13 1201a 31 123 213 8 
51 1 Pre-dose c 14 1301a 32 124 214 8 
75 1 Pre-dose c 15 1401a 33  215 6 
99 1 Pre-dose c 16 1501a 34  216 6 
123 1 Pre-dose c 17 1601a 35  217 6 
147 1 Pre-dose c 18 1701a 36  218 6 
171 1 Pre-dose c 19 1801a 37  219 6 
Follow  1 --- 20 1901a 38  220 6 
up         
phase          
Unscheduled 
Sampled --- --- 1001+  2001+  3001+  8 
a For the PK pre -dose samples (sample number 10-13 and 24 -38), the actual date and time of 
administration of the previous dose of study medication should also be recorded with appropriate Dose 
reference IDs as indicated in the above table.  
b Sampling to occur at steady state (week 15). If dose is interrupted and an infusion is delayed before 
week 15, the steady state sampling will occur after the dose has been resumed and [ADDRESS_892923] been given without interruption.  
c within 24hr before dose administration.  
  
 
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 72
7 Protocol No. 
  
 
[IP_ADDRESS]  Analytical  method 
The crizanlizumab PK assay is a target capture ELISA to determine the concentration of 
crizanlizumab remaining in serum samples. Concentrations below the lower limit of quantification  will be reported  as 0.00 ng/mL and missing  samples  will be labeled  accordingly. 
A pharmacodynamic marker of crizanlizumab is the ex vivo P- selectin inhibition measured by 
a surface plasmon resonance assay using human serum samples. Crizanlizumab in serum samples binds to spi[INVESTIGATOR_661865] -Ig (P -selectin coupled to Ig) and inhibits its binding to a PSGL1 
peptide. 
Immunogenicity determination will be performed using a bridging immunoassay format 
validated for Immunogenicity screening in human serum samples. 
Details of each analytical method will be given in bioanalytical data reports.  
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 73
7 Protocol No. 
  
 
 
 
7.2.5  Resource utilization  
Not applicable.  
 
7.2.6  Patient reported  outcomes  
Not applicable.  
 
8 Safety monitoring and  reporting 
8.1 Adverse events  
8.1.1  Definitions and reporting 
An adverse  event is defined  as the appearance  of (or worsening of any pre-existing) undesirable 
sign(s),  symptom(s), or medical  condition(s) that  occur  after  patient’s  signed informed  consent 
has been  obtained. 
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically significant, require therap y (e.g., hematologic abnormality that requires transfusion or hematological stem 
cell support), or require changes in study medication(s). 
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were already present at the time of informed consent should be recorded in the Medical History page of the patient’s CRF. Adverse event monitoring should be continued for at least 105 days (5 half -lives of crizanlizumab) following the last dose of 
study treatment. Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be reported as a separate Adverse Event.  
Adverse events  will be assessed  and graded  according  to the Common Terminology Criteria  for 
Adverse Events (CTCAE)  version 
If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, death  related  to the AE corresponding respectively  to Grades  1 - 5, will be 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 74
7 Protocol No. 
  
 
used. Information about any deaths (related to an Adverse Event or not) will also be collected 
though a Death form. 
The occurrence of adverse events should be sought by [CONTACT_105]- directive questioning of the patient 
during the screening process after signing informed consent and at each visit during the study. 
Adverse events also may be detected when they are volunteered by [CONTACT_655181], or through physical examination, laboratory test, or other assessments. As far as possible, each adverse event should be evaluated to determine:  
• The severity grade (CTCAE Grade 1-5) 
• Its duration (Start and end dates)  
• Its relationship to the study treatment (Reasonable possibility that AE is related: No,  Yes)  
• Action taken with respect to study or investigational treatment (none, dose adjusted for the 7.5 mg/kg dosage only, temporarily interrupted, permanently discontinued, unknown, not applicable)  
• Whether medication or therapy was given (no concomitant medication/non-drug therapy, concom itant medication/non -drug therapy) 
• Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.[ADDRESS_892924] been  met 
• Outcome (not recovered/not resolved, recovered/resolved, recovered/resolved with sequelae, fatal,  unknown). 
If the event  worsens the event should be reported  a second  time in the CRF  noting the start date 
when  the event  worsens  in toxicity.  For grade 3 and  4 adverse events  only, if improvement to a 
lower grade is determined a new entry for this event should be reported in the CRF noting the start date when the event improved from having been Grade 3 or Grade 4. 
All adverse events should be treated appropriately. If a concomitant medication or non-drug 
therapy is given, this action should be recorded on the Adverse Event CRF. 
Once  an adverse event  is detected,  it should be followed until its  resolution or until it is judged 
to be permanent,  and assessment  should be made at each visit (or more  frequently, if necessary) 
of any changes in severity, the suspected relationship to the study treatment, the interventions 
required to treat it, and the outcome. 
 
[IP_ADDRESS]  Protocol Exempt AEs & SAEs  
Protocol Exempt AEs & SAEs are implemented in the SEG101 program. VOCs must be reported on the VOC page in the eCRF. As VOCs are considered secondary endpoints for the purpose of evaluation  of efficacy,  AEs and SAEs  involving VOCs  SHOULD NOT  be reported 
as AEs or SAEs for the purpose of this study. These events will not be considered as SAEs in 
regards to reporting requirements.Vaso -occlusive crisis (including fatal outcomes), if 
documented by [CONTACT_661903] 7.2.[ADDRESS_892925] be reported to [COMPANY_001] within 24 hours of 
learning of the new information. 
The events in Table 8 -1 are the VOCs that will not b e reported as AEs/SAEs.  
 
Table 8-[ADDRESS_892926] of VOC Events Not Requiring AE/SAE  Reporting  
 
VOC Event  
Uncomplicated sickle cell -related pain crisis (SCPC) or vaso -occlusive crisis (VOC)*  
Acute chest syndrome  
Hepatic sequestration  
Splenic sequestration  
Priapi[INVESTIGATOR_49341] a visit to a medical facility  
*VOC is defined as pain crises (defined as an acute onset of pain for which there is no other 
medically determined explanation other than vaso- occlusion and which requires therapy with 
oral or parenteral opi[INVESTIGATOR_49342]) as well as other complicated crises, such as 
acute chest syndrome (ACS), p riapi[INVESTIGATOR_8801], and hepatic or splenic sequestration. 
 
8.1.[ADDRESS_892927]  abnormalities  
 
[IP_ADDRESS]  Definitions and reporting 
Laboratory abnormalities that constitute an Adverse event in their own right (are considered clinically  significant,  induce clinical  signs or symptoms, require  concomitant therapy  or require 
changes in study treatment), should be recorded on the Adverse Events CRF. Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be followed until they have returned to normal or an adequate explanation of the abnormality is found. When  an abnormal laboratory  or test result  corresponds to a sign/symptom of an already 
reported  adverse event,  it is not necessary  to separately  record  the lab/test result  as an additional 
event.  
Laboratory abnormalities, that do not meet the definition of an adverse event, should not be reported  as adverse events.  A Grade 3 or 4 event  (severe)  as per CTCAE  does not automatically 
indicate a SAE unless it meets the definition of se rious as defined below and/or as per 
investigator’s discretion. A dose hold or medication  for the lab abnormality may be required  by 
[CONTACT_217974], by [CONTACT_108], be an adverse event and must be reported as such . 
 
8.1.[ADDRESS_892928] (AESI) are defined as events (serious or non- serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for which ongoing monitoring and rapid communication by [CONTACT_81516]. Such events may require further investigation in order to characterize and understand them. 

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892929] are defined on the basis of an ongoing review of the safety 
data.  
 
8.2 Serious adverse  events  
8.2.1  Definitions  
Serious adverse event (SAE) is defined as one of the following: 
• Is fatal or  life-threatening  
• Note: fatal or life -threatening VOCs are not considered an SAE and should be recorded on 
the appropriate VOC eCRF  page 
• Results in persistent or significant disabil ity/incapacity  
• Constitutes a congenital anomaly/birth  defect  
• Is medically significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
• Requires inpatient hospi[INVESTIGATOR_1081],  
• Note that hospi[INVESTIGATOR_661866]:  
• Vaso -occlusive crisis as defined in the protocol 
• Routine treatment or monitoring of the studied indication, not associated with any deterioration in  condition 
• Elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
• Social reasons and respi[INVESTIGATOR_064]’s 
general condition 
• Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_217912] a SAE given above 
is not a serious adverse event 
 
8.2.[ADDRESS_892930] be reported  as follow-up to the original epi[INVESTIGATOR_5319]  24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 
interval or otherwise considered completely unrelated to a previously reported one should be reported separately as a new  event.  
Any SAEs experienced after the 105 day safety evaluation follow -up period should only be 
reported to [COMPANY_001] if the investigator suspects a causal relationship to the study treatment. 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically  

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892931] the relationship of each SAE to each 
specific study treatment (if there is more than one study treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to [COMPANY_001]. Detailed instructions regarding the SAE submission process and requirements for signatures are to be found in the investigator folder provided to each site. 
Each re -occurrence, complication, or progression of the original event should be reported as a 
follow-up to that event  regardless  of when  it occurs.  The follow-up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study participation.  
If the SAE is not previously documented in the Investigator’s Brochure and is thought to be related  to the [COMPANY_001]  study treatment,  an oncology [COMPANY_001] Chief  Medical  Office  and Patient 
Safety (CMO&PS) department associate may urgently require further information from the investigator for Health Authority reporting. [COMPANY_001] may need to issue an Investigator Notification  (IN),  to inform  all investigators involved in  any study with the same drug that  this 
SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the c ompetent authorities and relevant ethics committees in 
accordance with Directive 2001/20/EC or as per national regulatory requirements in participating  countries. 
 
8.[ADDRESS_892932] 
be reported  to [COMPANY_001]  within  24 hours of learning  of its  occurrence.  The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence  of any birth  defects,  congenital  abnormalities,  or maternal 
and/or newborn complications. 
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_436692] (CMO&PS). 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study treatment any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
Pregnancy outcomes should be collected for the female partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes should be obtained from the mother. 
 
8.[ADDRESS_892933] of the following: 
• What protected health information (PHI) will be collected from subjects in this  study 
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI. 
In the event that a subject revokes aut horization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission  to collect  follow-up safety  information  (e.g. has the subject 
experienced any new or worsened AEs) at the end of their scheduled study period. 
The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence  of individually assigned 
user identification  codes  and passwords, made  available  only to authorized  personnel who have 
completed prerequisite training. 
Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of  Birth), the system will prompt site to verify that this data is allowed to be collected. If 
the site indicates that country rules or ethics committee standards do not permit collection of these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the place of exact  date of birth) to  establish  that the subject  satisfies  protocol age requirements  and 
to enable appropriate age- related normal ranges to be used in assessing laboratory test  results.  
 
9.2 Site monitoring 
Before study initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] personnel (or designated CRO) will review the protocol and CRFs with the investigators and their staff. During the study, the field monitor will visit the site re gularly to check the 
completeness of patient records, the accuracy of entries on the CRFs, the adherence to the protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for  according to specifications. Key study 
personnel must be available to assist the field monitor during these visits. 

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892934] maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information recorded on CRFs must be traceable to source documents in the patient's file.  The investigator must also keep the original signed informed consent form (a 
signed copy is given to the patient). 
The investigator must give the monitor access  to all relevant  source documents to confirm  their 
consistency  with the CRF  entries.  [COMPANY_001] monitoring standards require full verification  for the 
presence of informed consent, adherence to the inclusion/exclusion criteria and documentation 
of SAEs. Additional checks of the consistency of the source data with the CRFs are performed accor ding to the study- specific monitoring  plan. 
 
9.3 Data collection 
The designated  investigator staff will enter  the data required  by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web- enabled so ftware that conforms to [ADDRESS_892935] certify that the data entered into the eCase Report Form is complete and accurate, and that entry and updates are performed in a timely manner.  
For PK, PD  samples, information about Treatment Periods, Visits, time points, 
and date and time of sample  collection  will be recorded  on the eCRFs  and also on the requisition 
forms sent to Central labs. A reconciliation of information regarding subjects and samples between the eCRF database and the lab database will be carried out by [CONTACT_661904] (or designated CRO). 
 
9.4 Database management and quality control 
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_5375]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies an d missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments  and prior medications  entered  into the database will be coded  using the 
WHO  Drug  Reference List, which  employs the Anatomical  Therapeutic Chemical  classification 
system. Medical history/current medical conditions and adverse events will be coded using the 
Medical dictionary for regulatory activities (MedDRA)  terminology. 
Any samples or data to be analyzed centrally (PK, PD,  central laboratory, central ECG reading) will be processed centrally and the results will be sent electronically to [COMPANY_001] (or a designated CRO). 
At the co nclusion of the study, the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 80
7 Protocol No. 
  
 
accurate, the database will be declared locked and made available for data analysis. 
Authorization is  required  prior to  making any  database changes  to locked  data,  by [CONTACT_661905],  the Global Head  of Data Management  and 
the Global Head of Clinical  Development. 
After database lock, the investigator will receive copi[INVESTIGATOR_105196].  
 
10 Statistical methods and data analysis  
The analysis  of study data for the primary  clinical  study report  (CSR)  will be based  on all patient 
data up to the time after the primary  PK and PD parameters  are available  for at least 27 patients 
for 5.0 mg/kg treatment  group in the PAS1  and PDS1  respectively,  or a total of [ADDRESS_892936] 
been enrolled in the 5.0 mg/kg treatment group, whichever occurs first. 
The additional data for any patients continuing to receive study drug past this time, as allowed by [CONTACT_760], will be further summarized in a final study report once these patients have 
completed or discontinued the study. 
 
10.1 Analysis sets  
10.1.1 Full Analysis  Set 
The Full Analysis Set (FAS)  comprises  all patients  to whom study treatment has been  assigned 
and who received at least one dose of study treatment. Patients will be analyzed according to the crizanlizumab dose (5.0 mg/kg or 7.5 mg/kg) they have been assigned to. 
 
10.1.[ADDRESS_892937] one dose of study treatment. Patients 
will be analyzed according to the dose level received (5.0 mg/kg or 7.5 mg/kg), where dose 
level received is defined as the assigned dose level if the patient took at least one dose of that treatment or the first dose received if the assigned dose level was never received.  
 
10.1.3 Pharmacokinetic analysis set  
The Pharmacokinetic analysis set 1 (PAS1) includes all patients who provide at least one evaluable PK profile. A profile is considered evaluable if all of the following conditions are satisfied: 
• Patient receives the planned treatment of 5.0 mg/kg or 7.5 mg/kg before single dose PK profile or 3 consecutive doses of the planned treatment before the multiple dose PK profile  
• Patient provides at least one primary PK parameter  
• Patient does not have any transfusion of blood product in the last [ADDRESS_892938] PK sample of the full PK profile, or during the full PK profile  
The Pharmacokinetic analysis set 2 (PAS2) includes all patients who receive at least one planned treatment of 5.0 mg/kg or 7.5 mg/kg and provide at least one corresponding evaluable PK concentration. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 81
7 Protocol No. 
  
 
10.1.4 Other analysis sets  
 
[IP_ADDRESS]  Pharmacodynamics analysis set 
The pharmacodynamics analysis set 1 (PDS1) includes all patients who provide at least one 
evaluable PD profile. A profile is considered evaluable if all of the following conditions are satisfied: 
• Patient receives the planned treatment of 5.0 mg/kg or 7.5 mg/kg before single dose PD 
profile or 3 consecutive doses of the planned treatment before the multiple dose PD profile  
• Patients provides at least one PD -AUC (single dose or multiple dose) parameter  
• Patient does not have any transfusion of blood product in the last [ADDRESS_892939] PD sample of the full PD profile, or during the full PD profile  
The pharmacodynamics analysis set 2 (PDS2) includes all patients who receive at least one planned treatment of 5.0 mg/kg or 7.5 mg/kg and provide at least one  corresponding evaluable 
PD assessment.  
 
[IP_ADDRESS]  Pharmacokinetic- Pharmacodynamics analysis set 
The pharmacokinetic -pharmacodynamics analysis set (PKPDS) includes all patients in the 
Safety set who have at least one trough concentration or one p- selectin  inhibition . 
 
10.2 Patient demographics/other baseline characteristics 
Demographic and other baseline data will be listed and summarized descriptively by [CONTACT_661906]. 
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented. 
Relevant medical histories will be summarized by [CONTACT_6657].  
 
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], 
compliance) 
The Safety set will be used for the analyses below. Categorical data will be summarized as 
frequencies  and percentages.  For continuous data,  mean,  standard deviation, median,  minimum, 
and maxi mum will be  presented.  
The duration of exposure in days to study drug as well as the dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dos e intensity) will be 
summarized by [CONTACT_360024].  
The number of patients with dose adjustments (interruption or permanent discontinuation) and the reasons will be summarized for all patients by [CONTACT_661907].  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 82
7 Protocol No. 
  
 
Concomitant medications and significant non- drug therapi[INVESTIGATOR_654542] (ATC) classification s ystem for all patients.  
 
10.4 Primary objective  
The primary objective is to characterize the PK and PD of crizanlizumab at 5.0 mg/kg in adult 
SCD patients.  
 
10.4.1 Variables  
The primary variables of the study are the PK and PD parameters after single dose and after 
multiple doses.  
 
Primary PK parameters:  
• AUCd15, AUCtau, Cmax  
The remaining PK parameters will be analyzed as secondary variables.  
 
PD parameters of crizanlizumab  
• PD-AUCd15 after single dose 
• PD-AUCd29 after multiple  doses 
10.4.[ADDRESS_892940] variations and CV% will be presented for the primary PK parameters. The 
point estimate and the corresponding two- sided 90% confidence interval (CI) for the mean of 
the log- transformed  primary  PK parameters  after single dose and multiple  doses  will be derived 
respectively.  The point estimate  and CI will be anti-log transformed  to obtain the point estimate 
and the 90% confidence interval for the geometric mean on the original scale.  
The descriptive statistics (n, mean, CV%, standard deviation (SD), median, geometric mean, geometric CV%, minimum and maximum) will be presented for all PK parameters de fined in 
Table [ADDRESS_892941] measurable concentration sampling time (tlast) 
(mass x time x volume -1) after single dose  
AUCtau  The AUC calculated to the end of a dosing interval (tau) at steady -state (amount x 
time x volume -1) 
Cmax  The maximum (peak) observed serum drug concentration after dose administration 
(mass x volume -1) 
Tmax  The time to reach maximum (peak) serum drug concentration after dose 
administration (time)  
Lambda_z  Smallest (slowest) disposition (hybrid) rate constant (time -1) 
T1/2 The half -life during a dose interval (time)  
The PAS1 for 5.0 mg/kg treatment group will be used for all PK analyses described above. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 83
7 Protocol No. 
  
 
Descriptive statistics for crizanlizumab concentration will be presented at each scheduled 
timepoint.  
All individual concentration- time profiles for cri zanlizumab with median will be displayed 
graphically  on semi -log view  after single and multiple  doses respectively.  In addition, the mean 
(+/- SD) and geometric mean concentration -time profiles over time will be displayed 
graphically on the linear and semi-log view.  
All individual PK parameters and PK concentration data for crizanlizumab will be listed.  
All individual pre -dose concentrations for crizanlizumab with median will be displayed 
graphically on semi -log view over time. In addition, the mean (+/ - SD) and geometric mean 
pre-dose concentrations over time will be displayed graphically  on the linear  and semi -log view.  
The PAS2 for 5.0 mg/kg treatment group will be used for these PK analyses. 
PD-AUCd15  and PD-AUCd29 will be derived  from  the P- selectin  inhibition  data of week  1 and 
week  15, respectively.  The point estimate  and the corresponding two-sided  90% CI for the mean 
of the log- transformed  PD-AUC  after single dose and multiple  doses will also be provided. The 
point estimate and CI will be anti -log transformed to obtain the point estimate and the 90% 
confidence interval for the geometric mean on the original scale.  
The PDS1 for 5.0 mg/kg treatment group will be used for all PD analyses described above. 
Descriptive statistics for PD inhibition will be presented at each scheduled timepoint. 
All individual PD -time profiles with median will be displayed graphically on semi -log view 
after single and multiple  doses respectively.  In addition, the mean  (+/- SD) and geometric  mean 
PD-time profiles over time will be displayed graphically on the linear and semi-log view.  
All individual PD parameters and PD data will be listed.  
Median pre -dose inhibition will be displayed graphically on semi -log view over time. In 
addition, the mean (+/- SD) and geometric  mean  pre-dose inhibition  over time will be displayed 
graphically on the linear and semi-log view.  
The PDS2 for 5.0 mg/kg treatment group will be used for these PD analyses. 
 
10.4.3 Handling of missing values/censoring/discontinuations  
Missing  values  for any PK parameters  or concentrations will not be imputed  and will be treated 
as missing.  
Below the limit of quantitation (BLQ) values will be set to zero by [CONTACT_638639], and will be 
displayed in the listings as zero and flagged. BLQ values will be treated as missing for the calculation of the geometric means and geometric CV%.  
Missing value s for the PD parameter or data will not be imputed and will be treated as missing.  
 
10.4.4 Supportive and Sensitivity  analyses  
Details will be provided in the Statistical Analysis Plan.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 84
7 Protocol No. 
  
 
10.5 Secondary objectives 
The secondary objectives in this study are to assess the efficacy, safety and tolerability of 
crizanlizumab at 5.0 mg/kg and 7.5 mg/kg in SCD patients. The FAS will be used for all analyses.  
 
10.5.1 Key secondary  objective(s)  
Not applicable.  
 
10.5.2 Other secondary effi cacy objectives 
The following endpoints will be summarized descriptively by [CONTACT_1570]. 
• Annualized rate of VOC events leading to healthcare visit in clinic/ER/hospi[INVESTIGATOR_307] 
• Annualized rate of VOC events treated at home, based on documentation by [CONTACT_661908]  
• Annualized rate of all VOC events (including both healthcare visit and home treatment)  
• Annualized rate of each subcategory of VOC event (uncomplicated pain crisis, acute chest 
syndrome, hepatic sequestration, splenic sequestration, priapi[INVESTIGATOR_8801])  
• Annualized rate of hospi[INVESTIGATOR_510727] (both overall and VOC -related)  
• Annualized days of hospi[INVESTIGATOR_510727] (both overall and VOC -related)  
10.5.3 Safety  objectives 
 
[IP_ADDRESS]  Analysis set and groupi[INVESTIGATOR_661867], the safety set will be used. All safety data will be summarized by [CONTACT_1570]. 
The overall observation period will be divided into three mutually exclusive segments: 
1. pre-treatment per iod: from day of patient’s informed consent to the day before first dose 
of study medication  
2. on-treatment period: from day of first dose of study medication to [ADDRESS_892942]- treatment period: starting at day [ADDRESS_892943] dose of study medication.  
 
[IP_ADDRESS]  Adverse events (AEs)  
Summary  tables  for adverse events  (AEs) will include only AEs that started  or worsened  during 
the on- treatment period, the treatment- emergent  AEs.  
The incidence of treatment -emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_30826], severity (based on CTCAE grades), type of adverse event, relation to study treatment by [CONTACT_1570]. 
Serious adverse events,  non-serious adverse  events  and adverse  events  of special  interest (AESI) 
during the on- treatment period will be  tabulated.  
All deaths (on-treatment and post- treatment) will be summarized.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 85
7 Protocol No. 
  
 
All AEs, deaths and serious adverse events (including those from the pre and post -treatment 
periods) will be listed and those collected during the pre -treatment and post -treatment period 
will be flagged. 
 
[IP_ADDRESS]  Laboratory  abnormalities  
Grading of laboratory values will be assigned programmatically as per NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory values only, clinical assessments will not be taken into account. 
CTCAE Grade 0 will be assigned for all non-missing values not graded as 1 or higher. For laboratory tests where grades are not defined by [CONTACT_3989] v4.03, results will be categorized 
as low/normal/high based on laboratory normal ranges. 
The following summaries  will be generated separately for hematology and biochemistry tests 
by [CONTACT_1570]: 
• Listing of all laboratory data with values flagged to show the corresponding CTCAE 
v4.03 grades if applicable and the classifications relative to the laboratory normal ranges  
For laboratory tests where grades are defined by [CONTACT_3989] v4.03 
• Worst post- baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only once for the worst grade observed post- baseline.  
• Shift tables using CTCAE v4.[ADDRESS_892944] on-treatment 
value 
For laboratory tests where grades are not defined by [CONTACT_3989] v4.03, 
• Shift tables using the low/normal/high/ (low and high) classification to compare baseline to the worst on- treatment value.  
In addition to the above mentioned tables and listings, other  analyses, for example figures plotting time course of raw or change in laboratory tests over time or box plots might be specified in the analysis plan. 
[IP_ADDRESS]  Other safety data 
ECG  
12 lead ECGs including PR, QRS, QT, QTcF and HR intervals will be obtained centrally for 
each patient during the study. ECG data will be read and interpreted centrally. 
The number and percentage of patients with notable ECG values will be presented. In addition, 
a listing of these patients will be produced. 
 
Vital signs  
Data on vital signs will be tabulated and listed, notable values will be flagged.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 86
7 Protocol No. 
  
 
[IP_ADDRESS]  Supportive analyses for secondary objectives  
Any supportive analyses that are considered appropriate for secondary variables will be 
described in the SAP prior to DBL. 
 
[IP_ADDRESS]  Tolerability  
Tolerability of study drug treatment will be assessed by [CONTACT_661909]. Reasons for dose interruption will be listed by [CONTACT_661910]. 
 
10.5.4 Pharmacokinetics  
Please refer to Section 10.4. 
 
  
 
 
10.5.6 Resource utilization  
Not applicable.  
 
10.5.7 Patient -reported outcomes  
Not applicable.  
 
10.5.8 Immunogenicity  
Immunogenicity will be characterized descriptively tabula ting antidrug antibodies (ADA) 
prevalence at baseline and ADA incidence on -treatment.  
 

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892945] 27 patients with single dose 
evaluable PK profiles and approximately 5 patients with both single dose and multiple dose evaluable PK profiles in the PAS1 for 5.0 mg/kg treatment group. Point estimate and 90% confidence intervals  for the primary  PK parameters  will be calculated.  PopPK modeling will be 
performed. Another interim analysis may be performed when there are approximately 15 patients  with multiple  dose evaluable PK profiles  in the 5.0 mg/kg treatment  group in the PAS1. 
Should the criteria  for the two interim analyses  be reached  at similar  times  compatible  with both 
objectives, a single combined interim analysis will be performed. Additional earlier or later ad hoc interim analyses of PK/PD/safety may be performed in order to support potential health authority requests.  
 
10.8 Sample size calculation 
5.0 mg/kg treatment group: 
For sample size consideration, PK and PD data from Study CSEG101A2101 and study 
CSEG101A2201 were used. Currently, the inter -subject variability of PK parameters, such as 
AUC  and Cmax,  of VOC  patients  is not known and needs  to be approximated from  the Ctrough 
results of patient study A2201. In that study the inter -subject variability of Ctrough was found 
to be 50.8%. 
Data of study A2101 has revealed  a high correlation  between  PK concentrations  336h post-dose 
and AUCt.  Assuming this correlation  holds true for patients  together with the assumption of an 

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892946]  CV = 50.8% of pre-dose concentrations allows  an approximation of expected  inter- 
subject CV = 46.1% for AUCt.  
Currently, the inter-subject variation  of the P- Selectin  inhibition  at 5.0 mg/kg  and the respective 
PDAUC672hr is not known. However,  approximations utilizing  results  from  lower  dose groups 
tested in study CSEG101A2101 suggest an inter -subject coefficient of variation of 
approximately CV =  34.1%. 
When  the sample  size is 27 evaluable patients,  a two-sided  90% confidence interval  for a single 
mean  of log- transformed  AUC  will extend  0.140 from  the observed  mean,  ensuring a precision 
of 15%, assuming that the standard deviation is known to be 0.439 and the confidence interval 
is based on the large sample z statistic.  
Similarly, with the same sample size of 27 evaluable patients, a two -sided 90% confidence 
interval for a single mean of log- transformed PD -AUC will extend 0.105 from the observed 
mean,  representing  a precision of about 11%, assuming that  the standard  deviation is  known to 
be 0.332 and the confidence interval is based on the large sample z statistic.  
After  the star t of trial A2202, new  information  was made available through the single dose HV 
study CSEG101A2102, in which PK variability for SEG101 was lower than for SelG1. Using the same process as described above, but this time starting from the CV% in A2102 SEG101 rather than A2101 SelG1, leads to the CV% for AUCt in patients being projected to be 34.7%, instead of 46.1%. 
With  such assumption for a lower  CV%,  a smaller  sample  size of 15 patients  would be sufficient 
to ensure the same precision  as originally  expected  with 27 evaluable  patients:  with 15 evaluable 
patients, a two -sided 90% confidence interval for a single mean of log- transformed AUC will 
extend 0.143 from the observed mean, still ensuring a precision of 15%, assuming that the 
standard deviation is known to be 0.3369 and the confidence inte rval is based on the large 
sample z statistic.  
However, considering the uncertainties around variability estimations (projected based on a single-dose HV study rather  than directly  observed in a multiple -dose patient study), the sample 
size of 27 for the primary analysis is maintained and an interim analysis will be conducted on 15 evaluable patients.  
Exploratory 7.5 mg/kg treatment group: 
When  the sample  size for this dose group is 6, a two-sided  90% confidence interval  for a single 
mean  will extend  0.[ADDRESS_892947]  deviation is known 
to be 0.209 and the confidence interval is based on t- statistic.  
Considering a drop- out r
 ate of 35% from the CSEG101A2201 study, and to account for the 
heterog eneity of patients in terms of genotype and renal function, the multiplication factor for 
enrollment versus evaluable patients is 67%, and 45 patients will need to be enrolled in the 5.0 
mg/kg treatment group. The same holds for the exploratory cohort, requiring enrollment of 10 patients to yield 6 evaluable patients at the 7.5 mg/kg dose. 
 
10.9 Power for analysis of key secondary variables 
Not applicable.  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 91
7 Protocol No. 
  
 
11 Ethical considerations and administrative  procedures  
11.1 Regulatory and ethical compliance 
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of Helsinki. 
 
11.2 Responsibilities of the investigator and IRB/IEC/REB 
The protocol and the proposed informed consent form must be reviewed and approved by a properly constituted Institutional Review Board/Independent Ethics Committee/Research Ethics  Board  (IRB/IEC/REB)  before  study start.  Prior to study start,  the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical Quality Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs/REBs and regulatory authorities as required.  
 
11.3 Informed consent procedures 
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB-approved informed consent 
Informed  consent must be obtained before  conducting any study- specific procedures (i.e. all of 
the procedures  described  in the protocol). The process  of obtaining informed  consent should be 
documented in the patient  source documents. The date when  a subject’s  Informed Consent was 
actually obtained will be captured in their CRFs.  
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP guideline and regulatory requirements. Any changes to this ICF suggested by [CONTACT_90219]/IEC/REB and a copy of the approved version must be provided to the [COMPANY_001] monitor after IRB/IEC/REB approval. 
Women of child bearing potential should be informed that taking the study medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the duration of the study. If there is any question that the patient will not reliably comply, they should not be entered in the study. 
 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 92
7 Protocol No. 
  
 
11.4 Discontinuation of the study 
[COMPANY_001] reserves  the right  to discontinue this study under the conditions specified  in the clinical 
study agreement. Specific conditions for terminating the study are outlined in Section  4.4. 
 
11.5 Publication of study protocol and results 
[COMPANY_001] is committed to following high ethical standards for reporting study res ults for its 
innovative medicine, including the timely communication and publication of clinical trial 
results, whatever their outcome. [COMPANY_001] assures that the key design elements of this protocol will be posted on the publicly accessible database,  e.g. wwwclinicaltrials.gov  before  study start. 
In addition, results of interventional clinical trials in adult patients are posted on wwwnovartisclinicaltrials.com, a publicly accessible database of clinical study results within  1 
year of study c ompletion  (i.e., LPLV),  those for interventional clinical  trials  involving pediatric 
patients within 6 months of study completion. 
[COMPANY_001] follows the ICMJE authorship guidelines (wwwicmje.org) and other specific 
guidelines of the journal or congress to w hich the publication will be submitted  
Authors will not receive remuneration for their writing of a publication, either directly from [COMPANY_001] or through the professional medical writing agency. Author(s) may be requested to present  poster  or oral  presenta tion at scientific  congress;  however, there will  be no honorarium 
provided for such presentations. 
As part of its commitment to full transparency in publications, [COMPANY_001] supports the full 
disclosure of all funding sources for the study and publications, as well as any actual and potential conflicts of interest of financial and non- financial nature by [CONTACT_15064], including 
medical writing/editorial support, if applicable.  
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsored R esearch, 
please refer to wwwnovartiscom. 
 
11.[ADDRESS_892948] keepi[INVESTIGATOR_217918], in 
compliance with Section  4.9 of the ICH  E6 GCP,  and regulatory and institutional requirements 
for the protection of confidentiality  of subjects.  As part of par ticipating  in a [COMPANY_001]-sponsored 
study, each site will permit  authorized  representatives  of the sponsor(s) and regulatory agencies 
to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress.  
Source data are all information, original records of clinical findings, observations, or other activities  in a clinical  trial necessary  for the reconstruction and evaluation  of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_10379], microfiches, photographic negatives,  microfilm or magnetic  media,  x-rays,  and subject  files and records  kept 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 93
7 Protocol No. 
  
 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical 
trial. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study case re port form (CRF) is the primary data collection 
instrument for the study. The investigator should ensure the accuracy,  completeness,  legibility, 
and timeliness  of the data reported  in the CRFs  and all other required  reports. Data reported  on 
the CRF, that are derived from source documents, should be consistent with the  source 
documents or the discrepancies should be explained. All data requested on the CRF must be recorded.  Any missing  data must be explained. Any change or correction  to a paper  CRF  should 
be dated, initialed, and explained (if necessary) and should not obscure the original entry. For electronic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator should retain records of the changes and corrections to paper CRFs.  
The investigator/institution should maintain the trial documents as specified in Essential Documents for the Conduct of a Clinical Trial  (ICH  E6 Section  8) and as required  by [CONTACT_5383]/or guidelines. The investigator/institution should take measures to prevent accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written permission to dispose of them or, requires their retention for an additional period of time because of applicable laws, regulations and/or guidelines. 
 
11.[ADDRESS_892949] ensure anonymity of the patients; patients  must not be identified  by [CONTACT_661911].  Signed informed consent forms  and patient  enrollment 
log must be kept strictly confidential to enable patient identification at the  site. 
 
11.8 Audits and inspections 
Source data/documents must be available to inspections by [CONTACT_447340].  
 
11.[ADDRESS_892950] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC/REB it cannot be implemented. All significant protocol deviations will be recorded and reported in the CSR.  

[COMPANY_001]  
Amended Protocol Version [ADDRESS_892951] be approved by [CONTACT_5343],  Health  Authorities  where  required, and the IRB/IEC/REB.  Only 
amendments that are required for patient safety may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any patient included in this study, even  if this action  represents  a deviation from  the protocol. In such cases, 
[COMPANY_001] should be notified of this  action  and the IRB/IEC at the study site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safety measures within 3 days) but not later than 10 working days. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 95
7 Protocol No. 
  
 
13 References (available upon  request)  
Ashley -Koch A, Yang Q, and Olney RS (2000) Sickle hemoglobin (HbS) allele and sickle cell 
disease: a HuGE review . Am J Epi[INVESTIGATOR_5541]; 151(9):839-45. 
Ataga KI, Kutlar A, Kanter J (2017) Crizanlizumab for the Prevention of Pain Crises in Sickle 
Cell Disease. N Engl J Med; 376 (5): 429-439. 
Bookchin RM and VL Lew (1996) Pathophysiology of sickle cell anemia. Hematol Oncol 
Clin North Am; 10(6):1241-53. 
Charache S (1996) Eye disease in sickling disorders. Hematol O ncol Clin North Am; 
10(6):1357-62. Chiang EY and Frenette PS (2005) Sickle cell vaso-occlusion. Hematol Oncol Clin North 
Am; 19(5):771-84 v. 
Dall'Acqua, W.F., et al (2002) Increasing the affinity of a human IgG1 for the neonatal Fc 
receptor: biological consequences. J Immunol; 169(9): 5171-80. 
Embury SH (2004) The not- so-simple process of sickle cell vaso -occlusion. Microcirculation; 
11(2):101-13. Frenette PS (2004) Sickle Cell Vaso -occlusion: Heterotypic, Multicellular Aggregations 
Driven by [CONTACT_661912]. Microcirculation; 11(2): 167-177. Geng JG, Bevilacqua MP, Moore KL, et al (1990) Rapid neutrophil adhesion to activated 
endothelium mediated by [CONTACT_49444]-140. Nature; 343(6260):757-60. 
Gill FM, Sleeper LA, Weiner SJ, et al (1995) Clinical events in the first decade in a cohort of 
infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood; 86 (2): 776- 
83. 
Gladwin MT, Sach dev V, Jison ML, et al (2004) Pulmonary hypertension as a risk factor for 
death in patients with sickle cell disease . N Engl J Med; 350(9): 886-95. 
Gladwin MT and Kato GJ (2005) Cardiopulmonary complications of sickle cell disease: role 
of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program: 51-7. 
Hamburger SA, McEver RP (1990) GMP- 140 mediates adhesion of stimulated platelets to 
neutrophils. Blood. 75(3): p. 550-4. Heegaard ED and KE Brown (2002) Human parvovirus 819. Clin Microbial Rev; 15(3):485- 
505. 
Hirschberg R (2010) Glomerular Hyperfiltration in Sickle Cell Disease. Clin J Am Soc 
Nephrol; 5:748-9. 
Jones DA, Abbassi O, McIntire LV, et al (1993) P- selectin mediates neutrophil rolling on 
histamine - stimulated endothelial cells. Biophys J; 65(4): p. 1560-9. 
Kaul DK and Hebbel RP (2000) Hypoxia/reoxygenation causes inflammatory response in 
transgenic sickle mice but not in normal mice . J Clin Invest; 106(3):411-20. 
Liu Z, Miner JJ, Yago T, et al (2010) Differential regulation of human and murine P- selectin 
expression and function in vivo. J Exp Med; 207(13): p. 2975-87. 
Maitre B, Habibi A, Roudot-Thoraval F, et al (2000) Acute chest syndrome in adults with 
sickle cell disease. Chest; 117(5):1386-92. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 96
7 Protocol No. 
  
 
Matsui NM, Borsig L, Rosen SD, et al (2001) P- selectin mediates the adhesion of sickle 
erythrocytes to the endothelium. Blood; 98(6):1955-62. 
McEver, R.P., K.L. Moore, and R.D. Cummings (1995) Leukocyte trafficking mediated by 
[CONTACT_661913]. J Biol Chem; 270(19): [ZIP_CODE]-8. 
McEver, R.P. (2004) Interactions of selectins with PSGL-[ADDRESS_892952] Schering 
Res Found Workshop; (44): 137-47. 
McClish DK, Penberthy LT, Bovbjerg VE, et al. (2005) Health related quality of life in sickle 
cell patients: The Pi[INVESTIGATOR_325130]. Health and Quality of Life Outcomes; 3: 50.  
Mehta, P., R.D. Cummings, and R.P. McEver (1998) Affinity and kinetic analysis of P- 
selectin binding to P-selectin glycoprotein ligand-1. J Biol Chem; 273(49): [ZIP_CODE]-13. 
NHBLI  Available from: http//wwwnhlbi.nih.gov/health/dci/Diseases/Sca/.  
NHLBI (2002) The Management of Sickle Cell Disease. NIH Publication No.022117. Nietert PJ, Silverstein MD, and Abboud MR (2002) Sickle cell anaemia: epi[INVESTIGATOR_661868]. Pharmacoeconomics; 20(6):357-66. 
NIH (2008) Hydroxyurea Treatment for Sickle Cell Disease February 25-27 2008. National 
Institutes of Health Consensus Development Conference Statement February 2008, 2008. 
NIH (2008) NIH State- of-the- Science Conference Statement o n Hydroxyurea Treatment for 
Sickle Cell Disease. NIH Consensus and State- of -the Science Statements; February 25 -27, 
2008. Vol. 25. 
Okpala I (2006) Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin 
Hematol; 13(1):40-4. 
Platt OS, Brambilla DJ, Rosse WF, et al (1994) Mortality in sickle cell disease. Life 
expectancy and risk factors for early death. N Engl J Med; 330(23):1639-44. 
Platt OS (2006) Prevention and management of stroke in sickle cell anemia. Hematology Am 
Soc Hematol Edu c Program; 2006:54-7. 
Saborio P and Scheinman JI (1999) Sickle cell nephropathy. J Am Soc Nephrol; 10(1):187-92. 
Sickle Cell Disease Guideline Panel. (1993) Sickle Cell Disease: Screening, Diagnosis, 
Management and Counseling in Newborns and Infants. Clini cal Practice Guideline No. 6. 
AHCPR Pub. No. 93 0562. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U. S. Department of Health and Human Services. April 1993. 
Smith JA (1996) Bone disorders in sickle cell disease. Hematol Oncol Clin North Am; 
10(6):1345-56. 
Springer, T.A (1995) Traffic signals on endothelium for lymphocyte recirculation and 
leukocyte emigration. Annu Rev Physiol; 57: 827-72. 
Thomas PW, Higgs DR, and Serjeant GR (1997) Benign clinical course in homozygous sickle 
cell disease: a search for predictors. J Clin Epi[INVESTIGATOR_5541]; 50(2):121-6. 
Vestweber, D. and J.E. Blanks (1999) Mechanisms that regulate the function of the selectins 
and their ligands. Physiol Rev; 79(1): 181-213. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 97
7 Protocol No. 
  
 
Vichinsky EP, Neumayr LD, Earles AN, et al (2000) Causes and outcomes of the acute chest 
syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Eng J Med; 
342(25):1855-65. 
Wagner MC, Eckman JR, and Wick TM (2006) Histamine increases sickle erythrocyte 
adherence to endothelium. Br J Haematol. 132(4): p. 512-22. 
Wethers, DL (2000) Sickle cell disease in childhood: Part II. Diagnosis and treatment of major 
complications and recent advances in treatmen t. Am Fam Physician; 62(6):1309-14. 
Wood, K., Russell J, Hebbel RP, et al (2004) Differential expression of E- and P- selectin in 
the microvasculature of sickle cell transgenic mice. Microcirculation. 11(4): p. 377-85. 
Yale SH, Nagib N, and Guthrie T (2000) Approach to the vaso- occlusive crisis in adults with 
sickle cell disease. Am Fam Physician; 61(5):1349-56, 1363-4. 
http//wwwaafporg/afp/2000/0301/p1349.html. 

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 98
7 Protocol No. 
  
 
14 Appendices  
14.1 Appendix 1 – List of prohibited CYP3A inhibitors and inducers 
The list of prohibited CYP3A inhibitors and inducers is provided in Table 14 -1 (this list may 
not be comprehensive). 
 
Table 14-[ADDRESS_892953] of prohibited CYP3A inhibitors and inducers 
 
Strong CYP3A 
inhibitors  Moderate CYP3A 
inhibitors  Strong CYP3A 
inducers  Moderate CYP3A 
inducers  
clarithromycin  amprenavir  carbamazepi[INVESTIGATOR_050] *  felbamate *  
conivaptan  aprepi[INVESTIGATOR_661869] *  topi[INVESTIGATOR_052] * (>200 mg/day)  
indinavir  atazanavir  phenytoin *  oxcarbazepin *  
itraconazole  cimetidine  fosphenytoin *  eslicarbazepin *  
ketoconazole  ciprofloxacin  primidone *  rufinamide *  
lopi[INVESTIGATOR_661870]. John's Wort  modafenil  
posaconazole  fluconazole   nafcillin  
ritonavir  grapefruit juice   ritonavir  
saquinavir  schisandra sphenanthera   talviraline  
telithromycin  tipranavir   tipranavir  
troleandomycin  tofisopam    
voriconazole  verapamil    
* These drugs are Enzyme Inducing Anti -Epi[INVESTIGATOR_006].  
This database of CYP inhibitors and inducers was compi[INVESTIGATOR_661871]’s  
“Clinically Relevant” Table, from the University of Washington’s Drug Interaction Database based on 
in vitro studies and from the FDA’s “Guidance for Industry, Drug Interaction Studies;” from the 
Indiana University School of Medicine’s “Clinically Relevant ” Table; and from (Pursche 2008).  

[COMPANY_001]  
Amended Protocol Version 01 Clean  Confidential  Page 99
7 Protocol No. 
  
 
14.2 Appendix 2 – List of prohibited QT-prolonging drugs 
All QT -prolonging drugs listed in Table 14 -2 are prohibited for all subjects from screening 
through permanent discontinuation of study. Table 14 -2 lists drugs with a known risk for TdP 
as well as sensitive CYP3A substrates (with narrow TI) with a possible or conditional risk for 
TdP.  
 
Table [ADDRESS_892954] of prohibited QT prolonging drugs 
 
Drug  QT risk(*)  Comment  
Amiodarone  Known risk for TdP  Females>Males, TdP risk regarded as low  
Arsenic trioxide  Known risk for TdP   
Astemizole  Known risk for TdP  No Longer available in U.S.  
Bepridil  Known risk for TdP  Females>Males  
Chloroquine  Known risk for TdP   
Chlorpromazine  Known risk for TdP   
Cisapride  Known risk for TdP  Restricted availability; Females>Males.  
Disopyramide  Known risk for TdP  Females>Males  
Dofetilide  Known risk for TdP   
Domperidone  Known risk for TdP  Not available in the U.S.  
Droperidol  Known risk for TdP   
Halofantrine  Known risk for TdP  Females>Males  
Haloperidol  Known risk for TdP  When given i.v. or at higher -than - recommended doses, risk of 
sudden death, QT prolongation and torsades increases.  
Ibutilide  Known risk for TdP  Females>Males  
Levomethadyl  Known risk for TdP   
Mesoridazine  Known risk for TdP   
Methadone  Known risk for TdP  Females>Males  
Pentamidine  Known risk for TdP  Females>Males  
Pi[INVESTIGATOR_360412]>Males  
Probucol  Known risk for TdP  No longer available in U.S.  
Procainamide  Known risk for TdP   
Quetiapi[INVESTIGATOR_360413] a sensitive 3A4 substrate  
Quinidine  Known risk for TdP  Females>Males  
Sotalol  Known risk for TdP  Females>Males  
Sparfloxacin  Known risk for TdP   
Tacrolimus  Possible risk for TdP  Prohibited as this drug is a sensitive 3A4 substrate with narrow 
TI 
Terfenadine  Known risk for TdP  No longer available in U.S.  
Thioridazine  Known risk for TdP   
Vardenafil  Possible risk for TdP  Prohibited as this drug is a sensitive 3A4 substrate  
(*)Classification according to the Qtdrugs.org advisory board of the Arizona CERT  
Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5-fold or higher when co- 
administered with a potent inhibitor of the respective enzyme.  
Note: drugs with a known risk for TdP that are also moderate or strong inhibitors of CY P3A mentioned  
 
